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ABSTRACT
Staphylococcus pseudintermedius is an opportunistic pathogen in dogs and
is the most frequent cause of canine pyoderma. The recent emergence of
methicillin resistance and multidrug resistance has made it increasingly difficult to
treat infections using conventional antibiotics. There is an urgent need for
alternative strategies to prevent S. pseudintermedius infections. The development
of a successful vaccine against S. pseudintermedius is complicated by several
virulence and immune evasion factors. The objective of this project was to identify
new targets for treatment and prophylaxis of methicillin-resistant and multidrugresistant S. pseudintermedius infection. This was achieved using two strategies
(a) understanding the roles of Protein A and Sortase A during pathogenesis, along
with exploring Sortase A inhibition as an alternate treatment strategy (b) analyzing
the surface-associated and secreted proteins in S. pseudintermedius to identify
novel vaccine targets.
In this study, a 3-D homology model for Sortase A was generated using
molecular dynamic simulation. Using this model, drug databases were screened
in silico and potential inhibitors of Sortase A were identified and tested in cell-free
and functional whole-cell assays. Four promising compounds were identified using
this strategy. Sortase A anchors proteins to the bacterial surface. These include
potent virulence and immune evasion factors such as Protein A. Both cell wallassociated and secreted Protein A in S. pseudintermedius was characterized and
its role in immune evasion was examined. Since Sortase A inhibition alone may
not be an effective treatment option, the entire secretome and the surfaceassociated proteins in S. pseudintermedius were analyzed by mass spectrometry.
Eight orthologous proteins across several S. pseudintermedius isolates were
identified that could serve as potential vaccine targets. Ultimately, Sortase A
inhibition along with a multicomponent vaccine containing a non-toxigenic version
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of Protein A and other potential B-cell/T-cell epitopes may be effective against S.
pseudintermedius infection.
This study is an important step in (i) understanding the nature of
immunoglobulin binding onto Protein A and (ii) the inhibition of Sortase A as an
alternate treatment strategy in S.pseudintermedius, and may ultimately pave the
way towards the development of a successful vaccine against S. pseudintermedius
infection.
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INTRODUCTION
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Introduction and Review of Literature
The recent emergence of methicillin resistance and multidrug resistance in
Staphylococcus aureus and Staphylococcus pseudintermedius has shifted the
focus of research from conventional antibiotic-based therapies to the development
of novel therapeutics or prophylactic means of dealing with these bacteria. This, in
part, has been a challenge due to the heterogeneity of the species. There are two
factors that play a crucial role in the development of a successful vaccine; (a) broad
understanding of the nature of host immune response to staphylococcal infections
and (b) the role of bacterial surface proteins and secreted virulence factors in
pathogenesis.

Introduction to Staphylococcus pseudintermedius
S. pseudintermedius is a Gram-positive coccus. It is a commensal and an
opportunistic pathogen in dogs, implicated as the most frequent cause of canine
pyoderma. It causes other infections, including those of the urinary tract, wounds,
and otitis externa. It has zoonotic potential and can cause sporadic infections in
humans as well [1-5]. S. pseudintermedius was classified as a new species in
2005. Until then, it was classified as S. intermedius. Since its reclassification,
S. pseudintermedius has been the most common staphylococcal species
associated with infections in dogs. As with any ‘new’ species, there is a lot to
discover in terms of genotype and phenotype and to understand any similarities or
differences at the molecular level. Much of what is known today about this
bacterium comes from comparative studies with S. aureus. Similar to S.aureus,
the incidence of methicillin resistance and multidrug resistance in this species has
been increasing in the past few years. This has made treatment of infection difficult
especially in the veterinary setting due to the limited number of drug choices that
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are available currently [6]. Therefore, there is an urgent need for the development
of alternate treatment strategies.

History and Characterization
Staphylococcus intermedius was first described in 1976 and was thought to be the
causative agent of skin infections in dogs. Advancements in molecular techniques
led to the identification of a novel species, S. pseudintermedius, in 2005 as the
causative agent of pyoderma and other skin infections in dogs [7]. Isolates that
were previously classified as S. intermedius based on phenotypic methods were
reclassified based on molecular typing methods. Thus, the Staphylococcus
intermedius group (SIG) was created consisting of three species, namely, S.
intermedius (type strain of pigeon origin), S. pseudintermedius (common causative
agent of skin infections in dogs) and S. delphini (first isolated from purulent skin
lesions of dolphins in 1988) [8].

Identification and Typing
Traditionally, isolates from canine skin infections had been identified by colony
morphology and standard phenotypic tests, but in recent times, this has been
complicated due to changes in the taxonomy of the species. Phenotypic methods
are not reliable for distinguishing between members of the SIG. S. intermedius can
be distinguished from S. pseudintermedius by a combination of biochemical tests
that include arginine dihydrolase test, β-gentiobiose test and D-mannitol test.
Currently, there are no known biochemical tests that can reliably distinguish
between S. pseudintermedius and S. delphini [7].Clinical identification of
S. pseudintermedius in a diagnostic setting relies on the fact that S. intermedius
and S. delphini are not associated with infections in dogs. Molecular methods are
the only way by which it is possible to correctly identify the species within the SIG.
3

Isolates previously identified as S. intermedius in dogs have now been classified
as S. pseudintermedius based on molecular typing methods [7, 8].

Molecular (Genomic) Methods for Species Identification

The first molecular method that was discriminative for S. intermedius and
S. pseudintermedius was phylogenetic analysis based on partial sequences of
sodA gene and hsp60 gene. Since then, various DNA-based methods have been
developed primarily for typing and epidemiological surveillance. These include
ribotyping, PFGE, spa typing, SCC-mec typing, and various PCR-based methods
[7, 8]. S. pseudintermedius can be distinguished from S. intermedius and
S.delphini

by

a

polymerase

chain

reaction-restriction

fragment

length

polymorphism (PCR-RFLP). This method relies on the presence of a single MboI
restriction site in the pta gene of S. pseudintermedius, which is absent in S.
intermedius and S.delphini. The only disadvantage of this method is the
heterogeneity associated with the MboI site in a small proportion of the
S.pseudintermedius strains which either results in the absence of the restriction
site or an additional band. A similar approach but with a different gene, the kat
gene harboring the restriction site for TaqI restriction endonuclease, has also been
evaluated for species identification of coagulase-positive staphylococci [8-10].
Another method for routine species identification of coagulase-positive
staphylococci in veterinary medicine is based on a multiplex PCR developed by
Sasaki et al. targeting the thermonuclease (nuc) gene [11].
Pulsed-field gel electrophoresis (PFGE) is one other method for bacterial typing in
general. It is based on analysis of the DNA fingerprint of the bacteria generated
upon treatment with selected restriction endonucleases. It has high discriminatory
power

compared

to

other

typing

methods.

PFGE

for
4

S. pseudintermedius is done using a protocol that was developed for S. aureus but
with slight modifications. Although this method is useful in studies investigating the
clonal relationships between MRSP isolates, it is time consuming and difficult to
standardize for inter-laboratory comparison. There are several modifications of the
protocol using the SmaI restriction endonuclease, making it difficult to share and
communicate PFGE data [7, 8, 12-14].
Staphylococcal Protein A (spa) typing developed by Moodley et al. is based on the
sequence variation of the polymorphic X-region of the spa gene. It is currently
employed for easy and rapid typing of S. pseudintermedius. It has high
discriminatory power and allows data sharing and harmonization between labs.
There are about 53 spa types, although an online database for this is currently not
available [5, 8, 15].
Multilocus Sequence Typing (MLST) is a valuable method for genotyping bacteria
based on variation in the sequence of slowly evolving housekeeping genes. Data
from MLST is portable, accurate and useful for global epidemiological studies
involving population genetic of bacteria. The earlier version of MLST was based
on four loci [16]. The current MLST scheme, which uses seven genes, developed
by Solyman et al. [6] has greater genetic diversity and discriminatory power
compared to other typing methods. The housekeeping genes used for this typing
scheme are tuf, cpn60, pta, purA, fdh, sar and ack. Based on the MLST scheme,
the predominant clonal population in the United States and Europe are designated
ST68 and ST71, respectively [12].
Staphylococcal chromosome cassette mecA (SCC mec) typing is based on the
sequence variation in the mobile genetic element (MGE), SCCmec. The SCCmec
region comprises the mecA gene, the cassette chromosome recombinase (ccr)
gene and three joining regions (J1-J3). The mecA gene is responsible for
5

conferring methicillin resistance. Therefore this typing method can be applied to
only methicillin resistant isolates. Based on the allotype of the ccr, the class of
mecA gene complex and sequence variation in the joining regions, there are at
least ten SCCmec types that are known, designated I-X [17] .
Automated systems designed for high-throughput screening and identification of
human pathogens such as microarrays may be used for S. pseudintermedius as
well, but because they are not designed for veterinary pathogens, their accuracy
in identification of veterinary pathogens is debatable. Most recently, a matrix
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF
MS) has been developed for species differentiation within the SIG [18].

Pathogenesis of S. pseudintermedius
S. pseudintermedius is an opportunistic pathogen. It does not cause any disease
unless the immune system of the host is compromised or there is a breach in the
external skin barrier, such as wounds and surgical procedures or other factors
predisposing

the

host

to

atopic

dermatitis.

The

pathogenesis

of

S. pseudintermedius remains largely unknown. Some genetic lineages and
sequence types are more virulent than the others and the reason behind this is not
fully understood [7] . Host factors likely play a crucial role in the pathogenesis of
S. pseudintermedius infection [8]. S. pseudintermedius adheres better to
corneocytes of atopic dogs whether sampled from an inflamed area or not, than
corneocytes of healthy dogs. There could be several reasons for this including a
change in the immune status of the dog or altered expression of surface adhesins
in atopic dogs compared to healthy dogs. More research in this area is needed to
fully understand the complex nature of host-pathogen interaction [19-21].

6

Virulence

Factors

and

Immune

Evasion

Factors

Produced

by

S. pseudintermedius

S. pseudintermedius produces a number of virulence factors, including some
functionally related to those produced by S.aureus [22]. Recent advancements in
genome sequencing technology and bioinformatics have added a wealth of
information to the current knowledge with respect to proteins and virulence factors
produced by S. pseudintermedius.
S. pseudintermedius produces several enzymes that are involved in virulence such
as coagulase, proteases, hyaluronidase, phospholipase, staphylokinase and
thermonuclease. It produces toxins such as leukocidins, exotoxins, leukotoxins,
exfoliative

toxins,

enterotoxins

and

hemolysins

[8].

S. pseudintermedius also has the ability to bind to fibrinogen, fibronectin and
cytokeratin using surface molecules that serve as microbial surface components
recognizing

adhesive

matrix

molecules

(MSCRAMM)

[8,

22].

S. pseudintermedius produces the immunoglobulin binding protein, Protein A,
which is similar to that found in S. aureus. Predicted Protein A genes from
S. pseudintermedius have been identified but their role in virulence and immune
evasion are yet to be determined [5].
Cytotoxins
S. pseudintermedius produces α-hemolysin and β-hemolysin and causes
hemolysis of rabbit erythrocytes and hot-cold hemolysis of sheep erythrocytes [2325].

The

β-hemolysin

from

S.

pseudintermedius

has

high-affinity

sphingomyelinase activity and is responsible for the characteristic partial zone of
hemolysis observed around colonies on sheep blood agar [8, 22]. It also produces
a bicomponent leukotoxins, Luk-I, encoded by two co-transcribed genes, lukS and
7

lukF, which has leucktoxic activity on polymorphonuclear cells. Luk-I is associated
with the most predominant clonal population in Europe, ST71, particularly
methicillin-resistant isolates [7, 8, 22].
Exfoliative toxin
S. pseudintermedius produces an exfoliative toxin called SIET. This toxin causes
a rounding effect on cultured epithelial cells. In animal models, SIET was shown
to cause an exfoliative effect in 1-day-old chickens, hamsters and dogs but not in
rats and mice. Dogs that were injected with purified SIET developed clinical signs
such as erythema, exfoliation and crusting similar to symptoms seen in canine
pyoderma, human staphylococcal scalded skin syndrome and porcine exudative
epidermitis (greasy pig disease). A second exfoliative toxin EXI (renamed ExpA)
encoded by the exi gene has been identified in S. pseudintermedius. The predicted
protein shows about 43-68% sequence identify with known staphylococcal
exfoliative toxins. A recombinant version of this protein caused exfoliative skin
lesions in neonatal mice. Apart from SIET and EXI, a third exfoliative toxin ExpB
has been identified in S. pseudintermedius, which causes intraepidermal splitting
and degradation of desmoglein-a (Dsg-1) [8, 22].
Enterotoxins and Superantigens
S. pseudintermedius produces proteins that cross-react with antibodies raised
against staphylococcal enterotoxins (SEs) and superantigens (SAs); SEA, SEB,
SEC, SED and toxic shock syndrome toxin-1 (TSST-1) [8, 22, 26]. A canine type
C enterotoxin (SEC canine) has been identified from canine pyoderma isolates. This
is distinct from other staphylococcal enterotoxins but shares their ability to induce
vomiting and T-cell proliferation [27]. A novel enterotoxin-related gene, se-int was
detected by PCR but its function remains to be examined [24, 28].
8

Cell-Wall Associated Proteins
Cell wall-associated (CWA) proteins, such as microbial surface components
recognizing adhesive matrix molecules (MSCRAMMs), play a crucial role in
bacterial attachment to the host extracellular matrix. The repertoire of MSCRAMMs
in each bacterial species contributes to its host adaptation and survival. CWA
proteins are characterized by an N-terminal signal sequence, LPXTG motif,
tandem repeats and immunoglobulin-like folds. Several CWA proteins have been
identified in S. pseudintermedius, designated as ‘Sps’ (Staphylococcus
pseudintermedius surface proteins). In particular, the isolate ED99 has at least 19
putative CWA proteins designated SpsA through SpsR [15, 29]. Many strains
adhere to fibrinogen, fibronectin, cytokeratin 10, elastin, collagen type 1, vitronectin
and laminin [29, 30]. Much remains to be understood about the interaction of S.
pseudintermedius with the host extracellular matrix.

Protein A
Protein A in S. aureus
Protein A is one of the most potent immune evasion factors in S. aureus [31]. It is
a cell wall-associated protein that binds to IgG from various mammals including
goat, rabbit, mouse and humans specifically via its Fcγ region. This binding in the
‘wrong’ orientation prevents it from binding to Fc receptors on immune cells such
as neutrophils, thereby preventing opsonization and phagocytosis [32-35] . Binding
of Protein A to IgG also prevents it from activating the complement via C1q. Both
the classical and alternate pathways of the complement can be inhibited by virtue
of this binding [36-39]. Thus, S. aureus evades the immune system and causes
persistent infections.
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Protein A is also secreted into the extracellular milieu during staphylococcal growth
and active infection [40-43]. The secreted form of Protein A functions as a B-cell
super antigen (SAg). It binds to VH3 B-cell receptors and limits their ability to
produce antibodies. Also, marginal zone B cells and B-1 cells undergo,
preferentially, induced cell death with supraclonal depletion and immune tolerance
upon exposure to Protein A. There is a clonal expansion at first followed by rapid
apoptosis of B-cells. Thus, Protein A may limit the efficacy of a vaccine that
depends on opsonophagocytic antibody production. It can also interfere with
vaccine efficacy by binding to B-cells and interfering with their function [44-48].

Structure and Function
Protein A is encoded by the spa (staphylococcal protein A) gene. The spa gene in
S. aureus is variable in length with approximately 1500bp. It encodes a protein of
about 480-500 amino acids with a molecular weight of ~40-60kDa [49, 50]. It is
synthesized as a precursor with an N-terminal signal sequence and a C-terminal
sorting peptide. The N-terminal part of SpA consists of four to five repeats of 5661 amino acids that serve as immunoglobulin binding domains (IgBD), designated
E,D,A,B and C, followed by a variable region, X [51]. The C-terminal region X is
comprised of Xr, a highly repetitive yet variable octapeptide, and Xc, a domain with
unique sequence in close proximity to the cell wall anchor structure of SpA [52].
The C-terminal also harbors an LPXTG motif which is recognized by the
transpeptidase enzyme Sortase A, responsible for anchoring the protein to the
pentaglycine residues of the peptidoglycan cell wall. Each IgBD folds into a triplehelical bundle, connected by short linkers with specific binding sites for Fcγ and
VH3 Fab domains of human and animal immunoglobulin. Glutamine (Q) residues
in position 9 and 10 in the α-helix 1 of each IgBD are critical for Fcγ binding, thereby
preventing antibody-mediated opsonization and phagocytosis. Aspartic acid (D)
residues in position 36 and 37 in the linker region between α-helix 2 and 3 of each
10

IgBD are essential for Fab binding of VH3-type IgG and IgM. This association
triggers the B-cell superantigen activity of Protein A. spa mutants have been shown
to be more susceptible to opsonophagocytic killing and are unable to block
adaptive immune responses in mouse models of S.aureus infection. Kim et al.
have demonstrated that a nontoxigenic Protein A variant, SpAKKAA, with 20 amino
acid substitutions replacing Q9 and Q10 with lysine (K) as well as D36 and D37 with
alanine (A) in each of the immunoglobulin binding domains, cannot bind Fcγ or VH3
Fab domains [53]. Immunization of mice with SpAKKAA elicited antibodies that
neutralized immunoglobulin-binding activities of Protein A, conferred some
protection in a mouse model of S. aureus infection, and augmented
immunogenicity of unrelated antigens [53, 54]. SpAKKAA monoclonal antibodies
promoted opsonophagocytic killing of S.aureus in mouse and human blood,
provided protection from abscess formation, and stimulated pathogen-specific
immune responses in a mouse model of staphylococcal disease [54, 55]. A
monoclonal antibody that specifically recognizes the E domain of SpA has also
been developed which neutralizes only the E domain of SpA but does not provide
disease protection in mice [44, 55].

Protein A in S. pseudintermedius
A putative staphylococcal protein A (spa) gene was initially described by Moodley
et al. in 2008 in the S. pseudintermedius isolate ED99 [5]. This gene was used to
develop a species-specific spa typing protocol. The spa gene in ED99 is 1389bp
in length and has 68% nucleotide and 55% predicted amino acid identity to the
homologous gene in the S. aureus reference strain 8325-4 where Protein A was
originally described. The predicted protein contained functional regions and
conserved domains similar to those described in S.aureus, including four IgGbinding domains and a polymorphic X-region [5, 15]. The sequence variation in the
variable region X in S. pseudintermedius had duplications or deletions of whole
11

repeats or point mutations within the repeats. Lack of IgG-binding domain region
B

(58

amino

acids)

partly

accounted

for

the

shorter

protein

in

S. pseudintermedius ED99 [5]. Bannoehr et al. in 2011 suggested that there were
two predicted orthologues of S. aureus Protein A in ED99, SpsP (designated as
Spa2) and SpsQ (which is a full-length Protein A designated as Spa1). The genes
are located along the oriC part of the genome and are adjacent to each other [15].
spsP
The spsP gene encodes a protein that consists of 377 amino acids in ED99. This
protein is 73% identical to SpsQ at the amino acid level. It has a predicted Nterminal sequence of 33 amino acids, followed by a repeat region consisting of
three predicted IgG-binding domains. Each IgG-binding domain consists of 55
amino acids with 78%-85% identity between domains. The C-terminal region has
a predicted X-region which shares 63% overall sequence similarity to the X-region
of S.aureus [15].
spsQ
The spsQ gene encodes a protein that is 462 amino acids in ED99. It has a
predicted N-terminal sequence of 33 amino acids, followed by a repeat region
consisting of four IgG-binding domains. Domains 1 and 2 have 59 amino acids;
domain 3 has 55 amino acids while domain 4 has 52 amino acids. The domains
have between 59%-86% protein sequence identity. The repeated IgG-binding
domains are conserved between SpsP and SpsQ, with 67% to 90% sequence
identity in pairwise alignments. The C-terminal region consist of a predicted Xregion which consists of a 77 amino acid-long repeat sequence (Xr) and a constant
region (Xc) with 70% similarity to the X-region of S. aureus. The Xr repeat region
of SpsQ was used by Moodley et al. to develop the spa typing method for S.
pseudintermedius

[5,

15].

Whole

genome

sequencing

of

several

S. pseudintermedius isolates in this lab has shown that most isolates have a full12

length spsQ gene while they may or may not harbor the full length spsP gene.
Some have a truncated spsP gene or the gene may be split into two separate
fragments.

Sortase A
Role of Sortase A in Protein Anchoring
Sortase A is a cysteine transpeptidase enzyme that is produced by most Grampositive bacteria. Surface proteins in Gram-positive bacteria play a crucial role
during pathogenesis. The main function of Sortase A is to anchor surface proteins
with an N-terminal LPXTG motif on to the peptidoglycan cell wall. Sortase A
substrates function as adhesins, internalins, blood clotting and immune evasion
factors, and transporters for nutrients across the microbial cell wall envelope [56].
Sortase A-deficient mutants of S. aureus fail to assemble LPXTG proteins on their
surface and are unable to form abscess lesions in organs or cause lethal
bacteremia in animal models of infection [57].
Sortase A is the prototypical enzyme for members of the class A family (housekeeping sortase) and has been widely studied. Sortase A is present in Firmicutes,
and is responsible for anchoring of proteins that mediate bacterial adhesion. Other
sortase genes and their corresponding enzymes have been identified. Class B
(sortase B) enzymes are responsible for attaching hemoglobin receptors to the
peptidoglycan cell wall and in the assembly of pili. These enzymes are also present
in Firmicutes. Class C sortases function as pilin polymerases and anchor pili on
bacterial surfaces. Class D sortases are found in bacilli and streptomyces and are
expressed during sporulation. Other less studied sortases include Class E and F
enzymes in actinobacteria whose functions are unknown [56, 58-60].

13

Sortase A in S. aureus

Structure and Function
Sortase A in S. aureus has been well studied and characterized. The srtA gene in
S. aureus is 618bp in length. It encodes a 206-amino acid protein with an Nterminal hydrophobic segment that functions as a signal peptide for secretion and
as a stop transfer signal for membrane anchoring. The C-terminal cell wall sorting
signal typically consists of a 35-reside peptide with an LPXTG motif, followed by a
hydrophobic domain and a positively charged tail [61]. The enzyme adopts a type
II membrane topology, with the N-terminus inside the cytoplasm and the C-terminal
enzymatic portion located across the plasma membrane [62]. NMR spectroscopy
and X-ray crystallography of Sortase A revealed that the enzyme assumes a
unique fold, consisting of an eight-stranded β-barrel that includes one or two
helices and several loops. Strands β7 and β8 form the floor of the hydrophobic
depression where the active site is located. Within the active site are the highly
conserved Cys184 and His120. The Cys184 is anchored in β7, while the His120 is
located within a helical region that connects β3 and β3, with its imidazole group in
the vicinity of the sulfhydryl side chain of Cys184. Arg197 is another amino acid
anchored in β8 that is located in close proximity and parallel to the active-site
cysteine [63]. Amino acid replacement of either Cys184 or His120 completely
abolished the activity of Sortase A both in vivo and in vitro and replacement of
Arg197 greatly reduced its enzymatic activity. Thr180, Ile182, and Ala118 are involved
in recognition and stabilization of bound substrate. Amino acid substitutions in
each of these residues can have profound effect on enzyme activity. It has been
observed that the presence of Ca2+ ions greatly enhances the activity of the
enzyme [56, 63-68].
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Surface proteins are synthesized in the bacterial cytoplasm as precursors
harboring an N-terminal signal peptide and a C-terminal sorting signal comprising
the LPXTG motif (P1 precursor) [64]. The surface proteins are then initiated into
the Sec secretion pathway. Signal peptidase cleaves the N-terminal signal peptide
to generate the P2 precursor. The hydrophobic domain of the sorting signal is
thought to retain the polypeptide in the membrane, thereby allowing the LPXTG
motif to be recognized by Sortase A. The sulfhydryl group of the active site Cys184
(possibly activated for deprotonation by Agr197) performs a nucleophilic attack at
the peptide bond between the threonine and glycine residue of the conserved
LPXTG. This generates an acyl-enzyme intermediate that undergoes a
nucleophilic attack by the amino group of the pentaglycine (Gly5) cross-bridge
within the peptidoglycan precursor lipid II and forms the P3 intermediate. P3
intermediates are subsequently covalently incorporated into the peptidoglycan cell
wall via the transpeptidation and transglycosylation reactions of the cell wall
biosynthesis, ultimately giving rise to the mature product (M). Thus, the surface
proteins are covalently linked at the C-terminal end to the cell wall envelope [56,
57, 63, 69].

Sortase A in S. pseudintermedius
Our lab is currently studying Sortase A and trying to find inhibitors that can
effectively block Sortase A activity. A putative srtA gene was identified from whole
genome sequences of various isolates representing the major clonal populations
in the United States and Europe. Based on the predicted protein sequence,
functional domains were identified. Sortase A in S. pseudintermedius is 57%
identical to S. aureus Sortase A at the protein level. They share the same sortase
family domains. Multiple sequence alignment of srtA gene from several S.
pseudintermedius isolates revealed that the gene is 597bp in length, 21bp shorter
than that found in S. aureus. It encodes a protein with 198 amino acids with a
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theoretical molecular weight of 22.3kDa. As with S. aureus Sortase A, it contains
highly conserved amino acids. Based on homology modeling and active site
prediction done as part of this project, Cys177, His114, and Arg190 are predicted to
be present in the active site and critical for enzyme activity. The crystal structure
and NMR spectra of S. pseudintermedius Sortase A are yet to be resolved.
However, based on the conservation of amino acids and predicted structural
similarity, it is hypothesized that Sortase A in S. pseudintermedius performs a
similar function as Sortase A in S. aureus. The predicted amino acid sequence of
Sortase A in S. pseudintermedius with the amino acids involved in catalytic activity
(highlighted) is as follows:
MQKLTRGLVPLIGIALILAGVYLIFKPKIDAYLTNKENEQKIEVYEESQQNAPSKVPEI
PKDPSKVVGVLEVPSVGIKEAVYPGPATPEQLERGVSLAEKDESLKDQNIAIAGHTNYS
LNYQFTELHKAKKGAEVIFKLGKETRKYQITSIKDVDPYQVEVLEEMKKDKDQLTLITC
DDYDEKTGQWLTRKIYVAERV

Inhibition of Sortase A and its Biological Effects
The recent emergence of methicillin resistance and multidrug resistance is a major
concern because conventional antibiotic treatments do not work against such
‘superbugs’ [56, 70]. Sortase A plays a crucial role in the pathogenesis of Grampositive bacteria by modulating the ability of the bacterium to adhere to host tissues
via the covalent anchoring of adhesins and other virulence factors onto the
peptidoglycan cell wall. S.aureus mutants lacking Sortase A fail to display surface
proteins and are defective in the establishment of infections in mouse models.
Therefore, inhibition of Sortase A is a promising strategy for treatment and
prevention of Gram-positive bacterial infections [56, 57, 71].
The idea of Sortase A inhibition was explored as early as in 1999 when Ton-That
and

Schneewind

demonstrated

that

methanethiosulphonstes

and
16

organomercurials displayed inhibitory effect on Sortase A. It was also observed
that vancomycin and moenomycin, two antibiotics that are inhibitors of cell wall
polymerization into peptidoglycan strands, inhibit Sortase A [64, 72]. Several
natural or chemical compounds ranging from plant extracts, alkaloids, and
flavonoids have been tested for their abilities to inhibit Sortase A in vitro with limited
success. Most of these compounds have been evaluated for the ability to inhibit
Sortase A in vitro by determining the IC50. There are several concerns with in vitro
inhibition based solely on IC50 values; (a) the mechanism of inhibition needs to be
completely understood i.e., whether the reaction is reversible or irreversible (b) the
enzyme kinetics assay parameters have to be evaluated (c) target site validation
studies have to be performed to determine if the inhibitor binds to the active site of
the enzyme or elsewhere in the polypeptide (d) the effect of the substrate on the
inhibition reaction i.e., whether or not there is competitive inhibition (e) the nature
of enzyme inhibition i.e., the effect of redox action, protein aggregation, pH
changes on inhibition and (f) the cytotoxic effects (if any) of the compounds. All
these factors need to be evaluated thoroughly before the inhibitor can be cleared
for use in humans or animals.
Recent advancements in proteomics and bioinformatics have made it possible to
identify novel inhibitors of Sortase A. Molecular Dynamic (MD) simulations
(modeling studies) can predict the binding/active site of the enzyme and also
facilitate rational design of inhibitors based on their affinities [73, 74]. There are a
large number of small molecules, drug-like libraries, and robotic automations that
allow for high-throughput screening [75]. Using synthetic chemistry and medicinal
chemistry, it is also possible to introduce side chain modifications or remove
reactive functional groups from the inhibitors such that the affinity of the inhibitor
to the enzyme to facilitate greater inhibition [76]. Several thousands of compounds
can be screened virtually and those compounds that display inhibitory potential
can then be tested in in vitro and in vivo models.
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Emergence of Methicillin Resistance and Multidrug Resistance
The emergence of methicillin resistance and multidrug resistance in staphylococci
has been an important problem both in human and veterinary medicine [77, 78].
Virulence genes and antibiotic resistance genes can be transferred between
isolates of the same species or between different species. This has the potential
to make a ‘drug-susceptible, avirulent’ strain resistant and highly virulent. There
are several ways by which this horizontal gene transfer (HGT) is mediated among
staphylococcal species. (a) Conjugation, mediated by plasmids, is one of the most
common and frequent methods of HGT. Plasmids carry several antibiotic
resistance genes and virulence genes that can be transferred to susceptible strains
upon successful conjugation. (b) Transduction, mediated by bacteriophages, is
another method by which susceptible strains acquire resistance and virulence
genes. (c) Transformation, which occurs via uptake of naked (exogenous) DNA
from the environment [79].
Resistance to methicillin is conferred by the mecA gene. This gene encodes
penicillin-binding protein 2A (PBP-2A) with reduced affinity for methicillin. The
mecA gene is contained within a mobile genetic element known as staphylococcal
cassette chromosome (SCCmec) [80]. Since its first report in 1999, the incidence
of methicillin resistance in staphylococcal isolates of canine origin has been
significantly increasing. Methicillin resistance in S.pseudintermedius is of major
concern because many of the methicillin resistant isolates are also multidrug
resistant [1, 78]. Treatment options are complicated due to the limited number of
drug choices to treat infections and the often extremely long and repeated
treatments needed to clear infections. The problem associated with prolonged use
of antibiotics, especially in terms of the prudent use of antimicrobials, is the
emergence of resistance [81].
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Towards Vaccine Development – Efforts and Reasons for Failure
As previously described, the increasing prevalence of antibiotic resistance among
staphylococci is a threat in both human and veterinary medicine [80, 82]. Nonantibiotic based alternate treatment strategies to efficiently combat staphylococcal
infections are urgently needed. Immunological strategies based on vaccine
development or therapeutic antibodies may have significant roles in the control of
staphylococcal infections. Vaccines are considered one of the most promising
approaches especially with the breakthrough of next generation sequencing
applications which provide novel methods for selecting antigens [22]. Most vaccine
targets are surface components of staphylococci or soluble virulence determinants
such as alpha-toxin, Panton-Valentine leukocidins, or superantigenic enterotoxins
[83]. Much effort has gone into vaccine development for S. aureus, yet none of
these have been translated into a commercially available protective vaccine. There
have been several reasons attributed to the failure of an S. aureus vaccine. First
of all, successful preclinical results obtained with antigens tested in clinical trials
were likely overestimated by vaccine manufacturers because antigens tested in
clinical trials provided only partial protection in mice. Also, the protective immunity
in mice cannot be directly translated into protective immunity in humans. Further,
vaccines tested in humans to date, since they all targeted single antigens, were
probably disproportionate to the complex pathogenic mechanisms of the
bacterium.
S. aureus produces a wide variety of immune evasion factors that complicate
vaccine development. In addition, the nature of protective immunity has not been
clearly understood which in turn has severely limited the ability to interpret both
preclinical and clinical data. Finally, the vaccines did not contain new generation
adjuvants, which may be critical in augmenting antibody production and steering
the T-cell response toward the proper profile of cytokine production [44, 84-86].
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Recent developments in whole genome sequencing and bioinformatics have made
it possible to identify novel vaccine candidates in a short span of time by replacing
time- consuming experimental tasks using in silico prediction steps. This way of
finding novel antigens has been called reverse vaccinology [87-89]. A successful
vaccine against staphylococcal infections should be able to elicit three major
immune responses:
(i)

Humoral immune response i.e., antibodies to directly inhibit bacterial
viability and/or toxicity

(ii)

Antibodies to facilitate opsonophagocytosis

(iii)

Cell-mediated T-helper 1 (Th1)/Th17 response [84].

However, there are a number of unresolved issues in vaccine development that
are yet to be elucidated; optimal antigenic target identification, criteria for
acceptable efficacy, identification of target population, optimal timing of
immunization strategy and storage to name a few [90].

Concluding Statement
The objective of this dissertation was to characterize the roles of Protein A and
Sortase A as potential targets for novel therapeutic approaches against
S. pseudintermedius infection, along with the analysis of the secretome and
surface-associated proteins in S. pseudintermedius by mass spectrometry to
identify novel antigenic and vaccine targets.
It is hypothesized that Protein A is a potent immune evasion factor in
S. pseudintermedius. Understanding the nature of Protein A and its role in
pathogenesis and immune evasion could lead to the development of a nontoxigenic Protein A vaccine that could be useful to treat S. pseudintermedius
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infection. The increase in methicillin resistance and multidrug resistance among
staphylococci has sparked interest in the development of novel non-antibiotic
based treatment strategies to combat this problem. One such attractive target in
S. pseudintermedius is Sortase A, the transpeptidase enzyme responsible for
anchoring proteins with an LPXTG motif onto the peptidoglycan cell wall. Many of
the LPXTG proteins function as potent virulence factors. Inhibition of Sortase A
could potentially lead to decreased surface expression of all those proteins
harboring the LPXTG motif, thus rendering the organism less virulent.
The development of a successful vaccine against S. pseudintermedius may
require a multicomponent vaccine, for which it is essential to identify novel antigen
and vaccine targets. Also, a good vaccine should include B-cell and T-cell epitopes
to facilitate the generation of both humoral and cell-mediated immune response,
thus resulting in protective immunity. This can be achieved by analyzing the
secretome and surface proteins using mass spectrometry and vaccine prediction
software.
The immune response to S. pseudintermedius has not been widely studied. A
deeper knowledge of the virulence factors and immune evasion factors will help
understand the pathogenesis of S. pseudintermedius. This will aid in the rational
design and development of vaccines and novel therapeutics, and will ultimately
pave the way towards treatment and prevention of S. pseudintermedius infections.
Therefore, I propose using Sortase A inhibition along with a multicomponent
vaccine containing non-toxigenic Protein A and other potent antigens as a potential
strategy against antibiotic-resistant S. pseudintermedius infection.

This dissertation is organized in a manuscript format. Each chapter is a
manuscript. Chapter 1 describes Protein A in S. pseudintermedius. In Chapter 2,
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the molecular basis for Protein A deficiency in the S. aureus strain Wood 46 has
been explained. As an important addition to this manuscript, the whole genome
sequence of Wood 46 was published and this is presented in Chapter 3. The
impact of Sortase A inhibition has been detailed in Chapter 4 followed by the mass
spectrometric analysis of the secretome and surface associated proteins in S.
pseudintermedius in Chapter 5.
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CHAPTER 1.
Protein A in Staphylococcus pseudintermedius
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Abstract
Staphylococcus pseudintermedius is an opportunistic pathogen in dogs and the
most frequent cause of canine pyoderma. Much of what is known today about
S. pseudintermedius comes from comparative research with Staphylococcus
aureus. Protein A, a potent virulence factor in S. aureus is encoded by the spa
gene. S. pseudintermedius possesses genes seemingly analogous to spa, but the
expression and the characteristics of their products have not been directly
determined, and the proteins they encode only share about a fifty percent identify
with S. aureus Protein A. The purpose of this study was to test isolates from major
clonal groups for the presence of spa gene orthologs, quantitate their expression
levels, and to characterize Protein A in S. pseudintermedius.
Results from conventional and quantitative real-time PCR suggest that
S. pseudintermedius isolates contain genes analogous to spa in S. aureus and the
mRNA could be quantified. Isolates representing the major clonal populations in
the United States and Europe, ST68 and ST71 respectively, bound significant
amounts of canine IgG and more than isolates with other genetic backgrounds.
Canine

IgG

bound

to

Protein

A

on

S. pseudintermedius via its Fc region similar to Protein A from S. aureus. The
expression profile of spa differed based on the sequence types and was correlated
to the density of Protein A on the bacterial surface. It was also observed that
Protein A was secreted during the exponential growth phase. Phagocytosis
experiments with S. pseudintermedius show that blocking Protein A enhanced
phagocytosis in whole blood, neutrophils and DH82 canine macrophage-like cell
line.

Taken

together,

the

results

demonstrate

that

S. pseudintermedius produces Protein A that shares S. aureus’ ability to bind the
Fc region of immunoglobulins and may serve as a potential virulence factor by
evading the host immune system.
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Introduction
S. pseudintermedius is the most common species of bacteria isolated from canine
pyoderma. Recently, this organism has developed widespread resistance to
methicillin [91-97] . Many methicillin-resistant S. pseudintermedius (MRSP) strains
are also multidrug resistant. In one study by Sasaki et al., all 18 of the MRSP
strains detected in their patients were resistant to erythromycin, clindamycin,
trimethoprim-sulfamethoxazole, and levofloxacin [98]. The emergence of
antimicrobial resistance has gradually shifted the focus of research in this field to
searching for prophylactic methods of control for these pathogens. Vaccine
development, however, requires a deeper understanding of the surface properties
and

virulence

mechanisms

of

the

various

strains

of

S. pseudintermedius
Several sequence types (STs) of S. pseudintermedius have been described, but
two in particular have been reported in significantly higher numbers than the rest:
ST68 in the United States and ST71 in European countries [6, 12, 99]. These two
sequence types are considered the most dominant and successful clonal
populations in their respective geographic locations, and the reason for their
success over other strains has yet to be elucidated.
Staphylococci have numerous defenses that allow evasion of the host immune
system including immunoglobulin binding proteins such as staphylococcal Protein
A. Protein A is produced by many species of staphylococci [31]. Within S. aureus
it is a 40–60 kDa cell-wall protein encoded by the spa gene [49, 50] and secreted
during exponential growth phase [41-43]. It is synthesized by nearly all S. aureus
isolates and binds to the Fc and Fab regions of immunoglobulins, [33, 35] inhibits
opsonophagocytic killing [31, 32, 100] and serves as a B cell superantigen [47, 48,
101]. Furthermore, marginal zone B cells and B-1 cells undergo, preferentially,
induced cell death with supraclonal depletion and immune tolerance upon
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exposure to Protein A [45]. Thus, Protein A may interfere with the efficacy of
vaccines that depend on opsonophagocytic antibody production by binding to Bcells and preventing their function [44]. On the other hand, antibodies directed
against Protein A have protected mice in experimental models of S. aureus
infection [53-55].
Putative Protein A activity has been correlated with virulence in S.
pseudintermedius; however, this conclusion was based on a semi-quantitative dot
blot IgG binding assay, did not take other immunoglobulin-binding proteins into
consideration or demonstrate the presence of spa genes

[102]. Genome

sequencing studies have shown that S. pseudintermedius contains genes
analogous to those encoding S. aureus Protein A as well as genes encoding other
IgG binding proteins [15]. A putative staphylococcal protein A (spa) gene was
initially described by Moodley et al. in 2008 in the isolate ED99 [5]. This gene was
used to develop a species-specific spa typing protocol. The spa gene ortholog in
ED99 is 1389bp in length and has 68% nucleotide and 55% predicted amino acid
identity to the homologous gene in the S. aureus reference strain 8325-4 in which
Protein A was originally described. The predicted protein contained a number of
functional regions and conserved domains that were previously described in S.
aureus, including four IgG-binding domains and a polymorphic X-region [5, 15].
Lack of IgG-binding domain region B (58 amino acids) partly accounted for the
shorter protein in S. pseudintermedius ED99 compared to Protein A in S. aureus.
[5] .
Bannoehr et al. in 2011 suggested that there were two predicted orthologues of S.
aureus protein A in ED99, SpsP (designated as Spa2) and SpsQ (which encodes
a full length protein A designated as Spa1) [15]. The spsP gene encodes a protein
that consists of 377 amino acids in ED99. This protein is 73% identical to SpsQ at
the amino acid level. It has a predicted N-terminal sequence of 33 amino acids,
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followed by a repeat region consisting of three predicted IgG-binding domains.
Each IgG-binding domain consists of 55 amino acids with 78%-85% identity
between domains. The C-terminal region has a predicted X-region which shares
63% overall sequence similarity to the X-region of S. aureus.
The spsQ gene encodes a protein that is 462 amino acids in ED99. It also has a
predicted N-terminal sequence of 33 amino acids, followed by a repeat region
consisting of four IgG-binding domains. The four IgG-binding domains vary from
59 amino acids for the first and second, to 55 amino acids for the third, and 52
amino acids for the fourth domain. They have between 59%-86% identity at the
protein level. The repeated IgG-binding domains are well conserved between
SpsP and SpsQ, with 67% to 90% sequence identity in pairwise alignments. The
C-terminal region consists of a predicted X-region which includes a 77 amino acidlong repeat sequence (Xr) and a constant region (Xc) with 70% similarity to the Xregion of S.aureus [5].
Whole genome sequencing of several S. pseudintermedius isolates [103] has
shown that most isolates have a full-length spsQ gene while they may or may not
harbor the full length spsP gene. It is not known, however, whether or not these
genes are expressed and produce functional protein in S. pseudintermedius or if
there are differences in the level of Protein A expression in different strains. The
purpose of this study was to characterize Protein A in S. pseudintermedius. In
order to determine this, the ability of S. pseudintermedius Protein A to bind canine
IgG and its digestion fragments, Fab and Fc, was determined. Gene expression
profiles were correlated with surface protein expression. In addition to surfaceassociated Protein A, secreted Protein A in S. pseudintermedius was also
investigated, because the secreted form might function as a potent superantigen.
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Materials and Methods
Bacterial Strains and Growth Conditions

S. pseudintermedius clinical isolates (Table 1.1) were used for all experiments. S.
aureus strain Cowan 1 and the S. pseudintermedius spa negative isolate 57395 (
a kind gift from Dr. Vincent Perreten, Institute of Veterinary Bacteriology, Vetsuisse
Faculty, University of Bern, Bern, Switzerland) were used as the positive control
and negative control strains for spa respectively wherever applicable. The strains
were selected based on their sequence types. Representatives from the most
prevalent sequence types in the US and Europe were used in this study. The
genetic background of the isolates was determined by multilocus sequence typing
(MLST) [6]. Bacteria from blood agar plates were grown overnight in 5ml of
Trypticase Soy Broth (TSB, Becton Dickinson, Franklin Lakes, NJ) at 37°C in a
shaker incubator at 225rpm. Fifty microliters of overnight culture was inoculated
into 5ml of fresh, sterile TSB and incubated for 3hr at 37°C with shaking to obtain
log phase cultures (OD600 = 0.4-0.6) which were used for all the experiments
unless mentioned otherwise.

DNA Extraction and Conventional PCR

Bacterial DNA was extracted from overnight cultures using a commercial kit
(MoBio Ultra Clean DNA Isolation Kit, MoBio, Carlsbad, CA) according to the
manufacturer’s protocol. PCR for detection of spsQ gene in clinical isolates was
performed

using

the

following

ATCTCAACCTGCTCCTGATTAC-3’

primers:
and

spa

spa

forward
reverse

5’5’-

GCATCTTTCGCTTTGTCCATAC-3’. The following cycling conditions were
performed: initial denaturation at 95°C for 90s, 30 cycles of annealing at 55°C for
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Table 1.1 Bacterial isolates used in this study along with their sequence type
and methicillin resistance profile
Strain

Sequence Type

Methicillin
Resistance

ED99

ST25

S

07 676c

ST29

R

08 547a

ST30

R

08 1781

ST43

S

57395 (spsQ negative)

ST45

R

08 1791

ST46

S

07 1447

ST54

R

NA47

ST56

S

NA12

ST64

R

06 3228

ST68

R

08 1294

ST68

R

08 521a

ST68

R

08 1661

ST71

R

E140

ST71

R

NA16

ST71

R

07 5066

ST83

R

NA45

ST84

R

KM241

ST93

R

30

30s and extension at 72°C for 1min followed by a final extension at 72°C for 5min.
PCR products were sequenced (The University of Tennessee Genomics Core
Facility), aligned and compared using Geneious 9.1.0 (Biomatters, Auckland, New
Zealand).

RNA Extraction and Quantitative Real-Time PCR
Total RNA was extracted from log-phase bacterial cultures using a commercial kit
(MoBio Ultra Clean RNA Isolation kit, MoBio, Carlsbad, CA) according to the
manufacturer’s protocol. Quantitative reverse-transcriptase PCR (RTqPCR) for
spsQ was performed using the TaqMan RNA-to-CT 1-Step kit on an ABI StepOne
PCR System (Applied Biosystems, Foster City, CA) using the primer-probe set :
5’-/56-FAM/CGCCAAGTT/ZEN/TCGATGAAGCGCAA/3IABkFQ/-3’,
5’CCGTTACGTTGCTCTTCAGTA-3’,

5’-TAACCAAACACCTACACAACCT-3’.

The following cycling conditions were performed: 48°C for 30min, 95°C for 10min
and 40 cycles of 95°C for 15s and 60°C for 1min. qPCR data were analyzed by
the ΔΔCT method and normalized against 16S rRNA as the endogenous control
as previously described [104].

Preparation of Canine Fab and Fc Fractions from Canine IgG and Biotin
Conjugation

Lyophilized canine IgG (IR-DG2-GF, Innovative Research, Novi, MI) was dissolved
in sterile PBS (pH 7.2). Canine Fab and Fc fractions were prepared using a kit
according to the manufacturer’s instructions (Pierce Fab preparation kit, Thermo
Scientific, Waltham, MA). Briefly, 1mg/ml of canine IgG equilibrated in digestion
buffer was added to papain (immobilized on beads) and incubated for six hours at
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37°C with shaking. Enzyme treated-IgG was then added to a Protein A column to
bind Fc fragments. Unbound Fab fragments were collected and Fc fragments were
eluted and immediately adjusted to neutral pH. All fragments were equilibrated in
PBS (pH 7.2).
Fc and Fab fragments prepared above and whole canine IgG were conjugated to
biotin (EZ-link NHS-PRG4-Biotin, No-Weigh Format, ThermoFisher Scientific,
Waltham, MA) according to the manufacturer’s protocol. Two milligrams each of
whole IgG, Fab and Fc were biotinylated. Unbound biotin was removed and the
fractions were equilibrated in PBS by ultrafiltration, and stored at 4°C until used.

Canine IgG Binding Assay

One milliliter of log phase bacterial culture was centrifuged at 10,000xg for 1min.
The bacteria were washed and suspended in 1ml of PBS and incubated with 100μl
of whole canine IgG (described above) at concentrations of 10μg/ml, 100μg/ml or
1000μg/ml for 30min at room temperature. The cells were washed twice with PBS
and incubated with 100μl of 1:100 dilution of goat anti-canine IgG (H+L)-FITC
conjugate (Southern Biotech, Birmingham, AL) for 30min at room temperature in
the dark. For the binding assay with canine Fab and Fc fractions, log phase
bacteria were incubated with 2μg/ml biotin-conjugated whole IgG, Fab or Fc
prepared previously at room temperature for 30min. Bacteria were washed as
before and incubated with 1:500 dilution of avidin-FITC conjugate (Sigma-Aldrich,
St. Louis, MO) at room temperature for 30min in the dark. The cells were washed
and the amount of binding was determined by flow cytometry.
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Protein A Binding Assay
One milliliter of log phase bacterial culture was centrifuged at 10,000xg for 1min.
The pellets were washed twice with PBS and resuspended in 1ml PBS and
incubated with 100μl of 1:100 dilution of chicken anti-Protein A-FITC conjugate
(Gallus Immunotech, Cary, NC) at room temperature for 30min in the dark.
Bacteria were washed again and the amount of binding was determined by flow
cytometry.

Competitive Binding Assay

One milliliter of log phase bacterial culture was centrifuged at 10,000xg for 1min.
The pellet was washed and suspended in 1ml PBS and incubated with 100μl of
1:100 dilution of chicken anti-Protein A antibody (Gallus Immunotech, Cary, NC)
for 30min at room temperature. The bacteria were washed as previously
described. One hundred microliter of 2µg/ml of biotin-conjugated canine Fc was
added and incubated at room temperature for 30min. After incubation, the bacteria
were washed and a 1:500 dilution of avidin-FITC conjugate (Sigma-Aldrich, St.
Louis, MO) was added and incubated for an additional 30min in the dark. Bacteria
were washed again and the amount of binding was determined by flow cytometry.

Enzyme Linked Immuno Sorbent Assay
Secreted Protein A in log-phase culture supernatants was measured using an
antigen capture ELISA. Briefly, 96-well flat bottom, costar plates (Corning Inc.,
Corning, NY) were coated overnight at 4°C with 1μg/ml of mouse monoclonal antiprotein A antibody clone SPA-27 (Mouse IgG1 isotype, Sigma-Aldrich, St. Louis,
MO,) in PBS. Bacterial supernatant containing secreted Protein A was added and
incubated at 37°C for 1 hour. Bound antigen was detected using a 1:500 dilution
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of HRP-conjugated chicken anti-protein A antibody (Gallus Immunotech, Cary,
NC) followed by addition of 100μl/well of tetramethylbenzidine (TMB) substrate
(Sigma-Aldrich, St. Louis, MO). Plates were washed in between each step with
PBS containing 0.05% polysorbate-20 using an ELX405 auto plate washer (BioTek
Instruments Inc., Winooski, VT). The reaction was stopped by adding 50μl/well of
0.18M sulfuric acid. The optical density was measured at 450nm using an ELX800
Universal Microplate Reader (BioTech Instruments Inc. Winooski, VT).

Labeling of Bacteria with pHrodoTM Red Amine-Reactive Label

Bacterial isolate 08-1661 (ST71) was labeled with pHrodo Red, succinimidyl ester
(pHrodoTM Red, SE, ThermoFisher Scientific, Waltham, MA) according to the
manufacturer’s instructions with minor variations. Briefly, 1mg of the pHrodoTM Red
SE was dissolved in 150μl of dimethyl sulfoxide (DMSO) to make a stock solution
of 10.2mM. 5ml of overnight bacterial culture was centrifuged 10,000g for 5 min
and the pellet was washed twice with phosphate buffered saline (PBS, pH 7.2).
One milligram of the pellet was resuspended in 750μl of fresh sodium bicarbonate
buffer, pH 8.5. The prepared dye was diluted into the bacterial suspension at a
final concentration of 1mM. The tubes were incubated at room temperature for 60
min in the dark with gentle rocking. After incubation, the cells were washed with
750μl of Hank’s balanced salt solution (HBSS, ThermoFisher Scientific, Waltham,
MA) by centrifugation at 15,000g for 1min. The bacterial pellet was resuspended
in 1ml of 100% methanol (Sigma-Aldrich, St. Louis, MO). Aggregates, if any, were
removed by gently vortexing. The bacteria were centrifuged again at 15,000xg for
1min to remove the methanol. Finally, the labeled bacteria were resuspended in
500μl of HBSS and stored in aliquots at -80°C until use.
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Whole Blood Phagocytosis Assay
A pH-sensitive dye, pHrodo Red, which fluoresces only in the acidic environment
of the phagolysosome was used to label bacteria in order to effectively visualize
phagocytosis and distinguish phagocytosed bacteria from those that are merely
adhered to the cell surface.
Fresh blood was collected in heparinized tubes from healthy dogs following an
approved IACUC protocol. Briefly, 100μl of blood was mixed with an equal volume
of pHrodoTM Red-labeled bacteria (containing 5X105 bacteria) and incubated at
37°C for 30min to facilitate phagocytosis. Control tubes containing all components
were incubated on ice for the same duration. After 30 min, phagocytosis was
stopped by addition of ice-cold PBS containing 5mM EDTA. The cells were washed
by centrifugation at 5000xg for 10min, suspended in 2ml of RBC lysing buffer
(Sigma-Aldrich, St. Louis, MO) and incubated at 37°C for 20min. The lysed RBCs
were removed by centrifugation. The pellet was washed twice with PBS and the
amount of phagocytosis was determined by flow cytometry. The same assay was
performed after isolating neutrophils from whole blood using a method described
previously [105] and the results were compared. .
Phagocytosis in DH82 Cells
The canine macrophage-like cell line, DH82, was obtained from the American Type
Culture Collection (ATCC, CLR-10389), propagated and maintained in Eagle’s
Minimum Essential Medium (EMEM, Quality Biological Inc., Gaithersburg, MD)
containing 15% heat-inactivated fetal bovine serum (Sigma Aldrich, St. Louis, MO)
and 1% penicillin/streptomycin/amphotericin-B mixture (Lonza, Walkersville, MD).
Cells were grown to confluency, trypsinized and seeded into 24-well costar tissue
culture plates (Corning Inc., Corning, NY) at a density of 1x106 cells per well and
allowed to adhere. pHrodoTM Red-labeled bacteria were added at an MOI of 100
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and incubated for 30min at 37°C to facilitate phagocytosis. A control plate with all
the components was incubated on ice for the same duration. After incubation,
phagocytosis was stopped by the addition of ice cold PBS containing 5mM EDTA.
The plate was allowed to sit for 5 min at room temperature. The PBS-EDTA was
gently aspirated and the adherent cells were harvested by standard trypsin
treatment for 5 min at 37°C. The contents from each well were transferred into a
vial and centrifuged at 5000g for 10 min. Cells were washed twice and suspended
in 1ml of PBS and analyzed by flow cytometry. Each sample was run in triplicate
and analyzed individually. Non-infected cells served as negative control to set the
cut-off for the discrimination of pHrodoTM Red-negative and -positive cells, and the
cells incubated on ice served as control to determine the percentage of
phagocytosis.

Flow Cytometry

Binding experiments with canine IgG, anti-Protein A antibody and phagocytosis
assay using labeled bacteria were performed by flow cytometry. The amount of
binding or phagocytosis was determined by measuring the fluorescence using an
Attune acoustic focusing cytometer (Applied Biosystems, Foster City, CA) at
excitation/emission wavelengths of 488/519 nm for green fluorescence and
560/585 nm for red fluorescence. Data were acquired in linear mode for forward
and side scatter and logarithmic mode for fluorescence. For each sample, 10,000
events were measured.
Statistical Analysis

A one-way ANOVA and multiple comparisons using Tukey’s honest significant
difference were performed to test if there was a significant difference in the
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expression of spsQ among bacterial isolates, and also to determine if there was a
significant difference in the amount of surface-expressed Protein A, secreted
Protein A and percentage of phagocytosed bacteria. Each experiment was
repeated at least three times and a p-value of <0.05 was considered significant.
All analyses were conducted using the GraphPad Prism software (Version 7,
GraphPad Software Inc, La Jolla, CA).

Results
S. pseudintermedius Contains Genes Analogous to spa in S. aureus

Whole genome sequences of isolates representing MLST sequence types ST68
(06-3228), ST71 (08-1661) and ST84 (NA45) were examined for the spa gene
ortholog [103]. Gene-specific primers were designed from a consensus sequence
after performing multiple sequence alignment, to amplify both the partial and fulllength spsQ gene. The PCR results showed that all but one isolate (the spsQ
negative isolate 57395) examined in this study contained the spsQ gene. Further,
sequence analysis of the spsQ gene from isolates representing ST68 and ST71
showed that they share 96% identity with that of the previously published spa gene
from ED99, while the spsQ gene from NA45 shared about 53% identity with that
of ED99. The spsQ gene sequences from 06-3228, 08-1661 and NA45 are
available in GenBank [103].

Expression of spsQ Gene in S. pseudintermedius

Reverse transcriptase qPCR was used to analyze the expression of spa in various
S. pseudintermedius isolates. The results showed that expression profiles of spsQ
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varied among sequence types. Isolates representing ST68 had lower expression
(approximately 1.5 log reduction) compared to isolates from ST71, but in general,
ST68 and ST71 isolates had higher spsQ expression than isolates from other
sequence types. The spsQ expression levels in isolates NA12, NA45 and KM241
could not be quantified because they were below the detection limits of the assay.
Isolate 57395, which was negative for spsQ, did not produce detectable amounts
of spsQ mRNA. spsQ expression levels were normalized against 16S rRNA as the
endogenous control and the results were expressed as fold change in mRNA
levels using the ΔΔCT method. To ensure equal amplification efficiencies of the
target and control genes, four 10-fold serial dilutions of the target RNA were tested.
The efficiencies of both the target gene and the endogenous control were
comparable (Figure 1.1).

Cell Wall-Associated Protein A in S. pseudintermedius

The density of surface-anchored Protein A in S. pseudintermedius was determined
by flow cytometry. Since there was no commercially available antibody against
Protein A from S. pseudintermedius, FITC conjugated anti-Protein A antibody
raised against S. aureus Protein A was used for this experiment. The amount of
binding was normalized against S. aureus Cowan 1 and expressed as percentage
bound relative to positive control. The results showed that isolates representing
ST68 and ST71 bound significantly more antibody compared to isolates
representing other sequence types suggesting that both ST68s and ST71s
express a higher density of Protein A on their
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Figure 1.1 Expression levels of spsQ.
qPCR was performed to measure the amount of spsQ mRNA in log phase bacterial
cells. Relative gene expression was calculated using the ΔΔCT method and
expressed as fold change. 16S rRNA was used as the endogenous control. The
values represent the average from three independent experiments. (*P<0.05 was
considered significant).
#

The spsQ mRNA levels in isolates NA12, NA45 and KM241were below the detection limits of the

assay.
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surface. Isolates 06-3228, 08-1294 and 08-521a (representing ST68) bound
34.47%, 20.94% and 27.54% of the labeled antibody respectively; while isolates
08-1661, E140 and NA16 (representing ST71) bound 40.77%, 29.92% and
38.26% of the labeled antibody respectively, relative to Cowan 1 (Figure 1.2).
Between isolates from ST68 and ST71, it was found that ST71 isolates bound a
higher percentage of the antibody, suggesting that these isolates may have a
higher density of Protein A on the surface. Since the antibody raised against
Protein

A

in

S.

aureus

recognizes

and

binds

to

Protein

A

on

S. pseudintermedius, Protein A in these two species apparently share epitopes,
however, differences between the two species may affect relative antibody
reactivity.

Canine IgG Reacts with Protein A on the Surface of S. pseudintermedius and
Binds to Protein A via its Fc Region

To determine if canine IgG binds to Protein A on the surface of
S. pseudintermedius, a binding experiment with canine IgG was performed.
Canine IgG was diluted 10-fold from 10μg/ml to 1mg/ml and incubated with log
phase cultures of various strains of S. pseudintermedius. A dose response was
observed for binding with increasing amounts of canine IgG (Figure 1.3),
suggesting

that

canine

IgG

recognizes

and

binds

to

Protein

A

on

S. pseudintermedius.
Isolates representing various sequence types (listed in Table 1.1) were reacted
with 100μg/ml of canine IgG. It was observed that isolates representing ST68 and
ST71 bound significantly more canine IgG than isolates from other sequence types
suggesting that they may have a higher density of cell-wall associated Protein A
on their surface (Figure 1.4).
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Figure 1.2 Protein A on the surface of S. pseudintermedius.
The

density

of

cell

wall-associated

Protein

A

in

various

strains

of

S. pseudintermedius was measured using FITC-conjugated anti-Protein A
antibody by flow cytometry. The values represent the average from three
independent experiments. (*P<0.05 was considered significant).
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Figure 1.3 Binding of canine IgG to Protein A on S. pseudintermedius (doseresponse).
A dose-response effect observed when varying concentrations of canine IgG
ranging from 10μg/ml-1000μg/ml was treated with S. pseudintermedius. The
values represent average from three independent experiments. (P<0.05 was
considered significant).
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Figure

1.4

Canine

IgG

recognizes

and

binds

to

Protein

A

on

S. pseudintermedius.
Isolates representing various sequence types of S. pseudintermedius were
reacted with 100μg/ml of canine IgG. The amount of binding was determined by
flow cytometry and expressed as percentage bound relative to the positive control
S. aureus Cowan 1 strain. The values represent average from three independent
experiments. (*P<0.05 was considered significant).
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After determining that canine IgG recognizes and binds to Protein A on
S. pseudintermedius, the next step was to examine which fraction of canine IgG
specifically binds to Protein A. Protein A in S. aureus binds to IgG primarily via its
Fc region [54]. It was hypothesized that Protein A in S. pseudintermedius also
binds IgG via its Fc region. In order to test this, canine IgG was digested with
papain to generate Fab and Fc fragments and reacted with bacteria. Two
microgram of each of the fragments, Fab and Fc, along with whole IgG were
reacted with various strains of S. pseudintermedius. The results showed that
Protein A in S. pseudintermedius binds to canine IgG via its Fc region (Figure 1.5).
Data for isolates representing the predominant sequence types 06-3228 (ST68),
08-1661 (ST71), NA12 (ST64) and NA45 (ST84) have been presented.

Anti-Protein A Antibody Inhibits the Binding of Canine Fc Fragment to
S. pseudintermedius

In order to determine whether anti-Protein A antibody (raised in chickens against
S. aureus Protein A) binds to Protein A on the surface of S. pseudintermedius, a
competitive inhibition assay was performed. Bacterial cells were incubated with
excess of unlabeled chicken anti-Protein A antibody prior to adding biotinconjugated canine Fc. Anti-Protein A antibody competitively inhibited the binding
of canine Fc as determined by a decrease in fluorescence when detected using
flow cytometry (Figure 1.6). A titration experiment was performed to determine the
optimal dilution of both the anti-Protein A antibody and the canine Fc fraction that
results in at least 50% reduction in binding of canine Fc. Data for isolates from
strains 06-3228 (ST68), 08-1661 (ST71), NA12 (ST64) and NA45 (ST84) have
been presented in (Fig 1.6). Since isolates NA12 and NA45 showed very little
binding to canine IgG and anti-Protein A antibody (Figure 1.2 and Figure 1.4),
these isolates were not expected to show any inhibition (Figure 1.6).
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Figure 1.5 Protein A binds to canine IgG primarily via its Fc region.
S. pseudintermedius isolates were treated with IgG and its papain digestion
fragments, Fab and Fc. The amount of binding was determined by flow cytometry.
The values represent average from three independent experiments. (*P<0.05 was
considered significant).
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Figure 1.6 Binding of anti-Protein A antibody prevents the binding of canine
Fc to Protein A on S. pseudintermedius.
Bacterial isolates were incubated with an excess of chicken anti-Protein A antibody
prior to the addition of canine Fc. There was at least 50% reduction in the binding
of canine Fc because of anti-Protein A antibody binding. The values represent
average from three independent experiments. (*P<0.05 was considered
significant).
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This further strengthened the fact that S. pseudintermedius expresses Protein A
on its surface and is recognized by the commercially available anti-Protein A
antibody.

Protein A in Bacterial Culture Supernatant

S. aureus isolates secrete Protein A into the culture supernatant during log phase
[41, 42]. In order to determine if S. pseudintermedius isolates also secrete Protein
A during log phase, a capture ELISA was used to measure the amount of Protein
A in bacterial culture supernatants. Log phase culture supernatants from various
bacterial isolates were tested. The results showed that isolates representing ST68
and ST71 secreted higher amounts of Protein A into the culture supernatant
compared to isolates from other sequence types. S.aureus Cowan 1, used as the
positive control, secreted 23.1ng/ml of Protein A. Isolates 06-3228, 08-1294 and
08-521 secreted between 0.98ng/ml-2.19ng/ml of Protein A. Isolates 06-1661,
E140 and NA16 secreted between 3.45ng/ml-9.94ng/ml of Protein A (Figure 1.7).
Among isolates from ST68 and ST71, a significant difference was observed in the
amount of secreted Protein A, with ST71s secreting higher amounts than ST68s.
As expected, isolate 57395, which was negative for the spsQ gene by both
conventional and quantitative real-time PCR did not produce detectable amounts
of Protein A. The lower limits of detection and quantification of the assay were
0.125ng/ml and 0.3ng/ml respectively. Taken together, these results suggest that
S. pseudintermedius not only expresses Protein A on its surface but also secrets
it into the culture supernatant during log phase.
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Figure 1.7 Production of extracellular Protein A in S.pseudintermedius.
The amount of extracellular Protein A was measured using an antigen-capture
ELISA. Commercially available Protein A from S.aureus was used to generate the
standard curve. The values represent the average from three independent
experiments. (*P<0.05 was considered significant).
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Binding of Anti-Protein A Antibody makes S. pseudintermedius more
Susceptible to Phagocytosis in Whole Blood, Canine Neutrophils and DH82
Cells

In order to determine if Protein A in S. pseudintermedius can function as an
immune evasion factor, phagocytosis was performed using canine whole blood,
neutrophils and DH82 canine macrophage-like cells. S. pseudintermedius isolate
08-1661 was labeled with a pH-sensitive dye, pHrodoTM Red which enables easy
visualization of phagocytosis. The labeled bacteria fluoresce in the acidic
environment of phagosomes, allowing the differentiation and visualization of
phagocytosed bacteria from those that are merely adhered to the cell surface.
The percentage of phagocytosis after 30min at 37°C in whole blood, neutrophils
and DH82 macrophage-like cells was 57.8%, 54.6% and 44.3% respectively
compared to the control which was incubated on ice for the same duration. To test
the involvement of Protein A in preventing phagocytosis, labeled bacteria were
pre-incubated with 100μg/ml of either chicken anti-Protein A antibody or canine
IgG before the start of phagocytosis. With both canine blood and neutrophils, preincubation of the bacteria with anti-Protein A antibody enhanced phagocytosis by
at least 10%, although this difference was not significant (Figure 1.8 and Figure
1.9). In DH82 cells however, phagocytosis was significantly enhanced by 17.8% in
the presence of anti-Protein A antibody (Figure 1.10) compared to the control
without anti-Protein A antibody. Canine IgG was also used in the experiment, but
it did not have any effect on phagocytosis. The duration for phagocytosis was
determined by a time course experiment and 30min was found to be optimal as
with previous studies involving S. aureus (Figure 1.11) [106, 107].
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Figure 1.8 Phagocytosis in whole blood.
The involvement of Protein A in immune evasion was demonstrated by
phagocytosis using pHrodoTM Red-labeled 08-1661 in whole blood. Incubation of
bacteria with anti-Protein A antibody enhanced phagocytosis. The values
represent average from three independent experiments. (*P<0.05 was considered
significant).
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Figure 1.9 Phagocytosis in neutrophils.
The involvement of Protein A in immune evasion was demonstrated by
phagocytosis using pHrodoTM Red-labeled 08-1661 in neutrophils. Incubation of
bacteria with anti-Protein A antibody enhanced phagocytosis. The values
represent average from three independent experiments. (*P<0.05 was considered
significant).
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Figure 1.10 Phagocytosis in DH82 canine macrophage-like cell line.
The involvement of Protein A in immune evasion was demonstrated by
phagocytosis using pHrodoTM Red-labeled 08-1661 in DH82 canine macrophagelike cell line. Incubation of bacteria with anti-Protein A antibody significantly
enhanced phagocytosis. The values represent average from three independent
experiments. (*P<0.05 was considered significant).
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Figure 1.11 Phagocytosis of pHrodoTM Red-labeled 08-1661.
Time-course experiment to demonstrate phagocytosis at 37°C and a control
experiment at 0°C.
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Taken together, these results suggest that Protein A in S. pseudintermedius could
function as an immune evasion factor similar to Protein A in S. aureus, and prevent
bacteria from being opsonized and phagocytosed.

Discussion
Protein A is a widely studied virulence and immune evasion factor. Nearly all
S. aureus isolates are known to produce Protein A [31]. It is expressed on the
peptidoglycan cell wall and is also secreted into the bacterial culture supernatant
during exponential growth phase [41-43, 49, 108]. One of the most important
features of Protein A is its ability to bind IgG via its Fc region, thereby preventing
opsonization and phagocytosis [33-35]. This helps the bacteria evade the host
immune response, leading to persistent infections [32, 36, 37, 100].
S. pseudintermedius, the canine pathogen implicated as the causative agent of
pyoderma also contains genes predicted to encode Protein A [7, 15]. Protein A in
S. pseudintermedius has not been previously studied or characterized.
In this study, the presence of cell-wall anchored Protein A was measured by flow
cytometry. It was found that Protein A is a component of the cell wall of most of the
isolates tested in this study (Fig 1.2). It was also found that canine IgG was able
to react with Protein A on the surface of S. pseudintermedius. Protein A on S.
pseudintermedius bound to canine IgG via its Fc fragment (Fig 1.4 and Fig 1.5)
suggesting that it may escape phagocytosis and serve as an immune evasion
factor. It should be noted that the anti-Protein A antibody used in this study is raised
against S. aureus Protein A. Also, canine IgG used in this study could be binding
the bacterial surface via its Fab region. In fact, isolate 57395 which was negative
for the spa gene by conventional PCR showed some binding to anti-Protein A
antibody.

Since

this

antibody

is

raised

against

S.

aureus
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Protein A, there is a possibility that it reacts with other surface proteins, particularly
immunoglobulin binding proteins like Sbi, besides Protein A on the surface of S.
pseudintermedius. This is true in the case of S. aureus, where spa deletion
mutants have been shown to bind with anti-Protein A antibody [109-111]. Isolates
from the dominant clonal populations in the United States and Europe, ST68 and
ST71, bind more IgG and have a higher density of Protein A on their surface than
isolates of other STs. This property could explain why isolates from ST68 and
ST71 are so successful in the population compared to other sequence types. The
presence of extracellular Protein A in S. pseudintermedius suggests that it could
also function as a superantigen. Phagocytosis experiments with whole blood,
neutrophils and DH82 macrophage-like cells indicate that blocking bacterial
surface Protein A with anti-Protein A antibody makes it more susceptible to
phagocytosis. Taken together, the results suggest that Protein A in S.
pseudintermedius may share common features with its S. aureus counterpart, and
serve as a potent virulence factor.
Vaccine studies with S. aureus have indicated that a multivalent vaccine with
different epitopes would probably work best [44, 84, 112]. Keeping the same
factors

in

mind,

the

successful

development

of

a

vaccine

against

S. pseudintermedius would involve identifying antigenic targets representative of
a wide variety of strains and sequence types. Understanding the nature of surface
proteins and their role in virulence and pathogenesis is critical for vaccine
development against S. pseudintermedius infection.
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CHAPTER 2.
Molecular Basis of Surface Anchored Protein A Deficiency in the
Staphylococcus aureus Strain Wood 46
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Abstract
Protein A in Staphylococcus aureus is encoded by the spa (staphylococcal protein
A) gene and binds to immunoglobulin (Ig). The S. aureus strain Wood 46 has been
variously reported as Protein A-deficient and/or spa negative and used as a control
in animal models of staphylococcal infections. The results of this study indicate
that Wood 46 has normal spa expression but transcribes very low levels of the srtA
gene which encodes the Sortase A (SrtA) enzyme. This is consistent with unique
mutations in the srtA promoter. In this study, a low level of Sortase A explains
deficient anchoring of proteins with an LPXTG motif, such as Protein A, fibrinogenbinding protein and fibronectin-binding proteins A and B on to the peptidoglycan
cell wall. The activity of secreted Protein A is an important consideration for use of
Wood 46 in functional experiments and animal models.

Introduction
Protein A produced by S. aureus is a potent virulence factor and immunemodulator [31, 113-116]. It is a 40–60 kDa cell-wall protein encoded by the spa
gene [49, 50]. It is synthesized by nearly all S. aureus isolates and binds to the Fc
and F(ab)2 regions of immunoglobulins [33, 35], prevents opsonophagocytic killing
[31, 32, 100] and serves as a B-cell superantigen [47, 48, 101]. Furthermore,
marginal zone B cells and B-1 cells undergo, preferentially, induced cell death with
supraclonal depletion and immune tolerance upon exposure to Protein A [45].
Thus, Protein A may interfere with vaccine efficacy that depends on
opsonophagocytic antibody production by binding to B-cells and preventing their
function. The S. aureus strain Wood 46 had been considered spa negative and
Protein A-deficient. For this reason, it was used as a negative control in studies
involving S. aureus virulence [31, 117-123]. There is evidence that Wood 46
produces extracellular Protein A during exponential growth phase and steady state
[119]. This has been demonstrated indirectly by immunoglobulin binding
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experiments [119]. Extracellular Protein A has also been isolated from Wood 46
using IgG Sepharose chromatography, although the amount of putative Protein A
recovered from Wood 46 is lower compared to S. aureus strain Cowan 1, a high
producer of Protein A [118, 119]. S.aureus produces a second immunoglobulinbinding protein (Sbi), which is also capable of binding to the Fc portion of IgG
similar to Protein A and protects the bacteria against innate immune responses
[109].
Sortase A (SrtA) is a transpeptidase commonly produced by Gram-positive
bacteria. It has specificity for proteins with an LPXTG motif and cleaves between
the threonine (T) and glycine (G) residues to form an acyl enzyme intermediate
that is relieved by the nucleophilic attack of the amino group in the pentaglycine
cross bridge of the peptidoglycan precursor[62]. Modified proteins are
subsequently incorporated into the peptidoglycan cell wall and displayed on the
surface [56, 62-64, 66, 108, 124]. S. aureus isolates encode approximately 17-21
surface proteins with an LPXTG motif [70, 115, 125]. These include Protein A,
fibrinogen-binding proteins - clumping factors A and B (Clf A/B) and fibronectin
binding proteins (FnBP A and FnBP B) that function as potent virulence factors
[126]. S. aureus mutants lacking SrtA fail to covalently attach proteins with an
LPXTG motif onto their cell wall, and are thus less virulent than their wild-type
counterparts. They do not form abscess lesions in organs or cause bacteremia in
mouse models [70, 74]. In this study, the reason for Protein A deficiency on the
surface of Wood 46 was investigated and the defective expression of spa and srtA
genes encoding functional proteins was examined as a possible cause.
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Materials and Methods
Bacterial Strains and Growth Conditions

S. aureus strain Wood 46 (ATCC 10832), Seattle 1945 (ATCC 25923) and Cowan
1 (ATCC 12598) were obtained from the American Type Culture Collection. The
S. aureus Newman strain and its corresponding spa and sbi mutants (Newman
WT, Newman sbi::Emr, Newman spa::Kar and Newman sbi::Emr spa::Kar) were a
kind gift from Drs. Tim Foster and Joan Geoghegan (Department of Microbiology,
Trinity College Dublin) [109]. Bacteria were grown overnight in Trypticase Soy
Broth (TSB, Becton Dickinson, Franklin Lakes, New Jersey) at 37°C in a shaker
incubator and diluted 1:50 in fresh TSB to initiate log-phase cultures.

DNA Extraction and Conventional PCR

Bacterial DNA was extracted from overnight cultures using a commercial kit
(MoBio Ultra Clean DNA Isolation Kit, MoBio, Carlsbad, CA) according to the
manufacturer’s protocol. PCR for spa, srt A and the -35 regulatory region was
performed using primers listed in Table 2.1. The following cycling conditions were
performed: initial denaturation at 95°C for 90s, annealing at 55°C for 30s and
extension at 72°C for 1min (30 cycles), and a final extension at 72°C for 5min. PCR
products were sequenced (The University of Tennessee, Genomics Core Facility)
and the sequences of spa, srtA and the regulatory region in all isolates were
aligned and compared using Geneious (version 9.1.6) (Biomatters, Auckland, New
Zealand).
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RNA Extraction and Quantitative Real-Time PCR
Total RNA was extracted from log phase bacterial cultures using a commercial kit
(MoBio Ultra Clean RNA Isolation kit, MoBio, Carlsbad, CA) according to the
manufacturer’s protocol. Quantitative Real-Time PCR (qPCR) for spa and srt A
were performed using the TaqMan RNA-to-CT 1-Step kit on an ABI StepOne PCR
System (Applied Biosystems, Foster City, CA). The primers and probe used for the
qPCR are listed in Table 2.1. The following cycling conditions were performed:
48°C for 30min, 95°C for 10min, followed by 40 cycles of 95°C for 15s and 60°C
for 1min. qPCR data were analyzed by the ΔΔCT method and normalized against
16S rRNA as the endogenous control as previously described [104].

Protein A ELISA
Secreted Protein A in culture supernatants was measured using an antigen
capture ELISA. Briefly, 96-well Costar plates (Corning Inc, Corning, NY) were
coated with 1μg/ml of mouse monoclonal anti-protein A antibody clone SPA-27
(Sigma-Aldrich, St. Louis, MO) in PBS pH 7.2. Bacterial supernatant was added
and incubated at 37°C for 1 hour. Bound antigen was detected using a 1:500
dilution of HRP-conjugated chicken anti-protein A antibody (Gallus Immunotech,
Cary, NC) followed by addition of 100μl/well of tetramethylbenzidine (TMB)
substrate (Sigma-Aldrich, St. Louis, MO). Plates were washed in between each
step with PBS containing 0.05% polysorbate-20 using an ELX405 auto plate
washer (BioTek Instruments Inc., Winooski, VT). The reaction was stopped by
adding 50μl/well of 0.18M sulfuric acid. The optical density was measured at
450nm using an ELX800 Universal Microplate Reader (BioTech Instruments Inc.
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Table 2.1 List of primers used in this study
Gene

Primers

Reference

spa

F 5’-ATCTGGTGGCGTAACACCTG-3’

This study

(conventional R 5’-CGCTGCACCTAACGCTAATG-3’
PCR)
srtA

F 5’-AAGCGTTTCGTTATTTGAATGC-3’

This study

(conventional R 5’-TCGTCATTGCTACCTCATACC-3’
PCR)
spa (qPCR)

5’-/56-

This study

FAM/TTTGTCAGC/ZEN/AGTAGTCGCGTTT
GC/3IABkFQ/-3’
5’-ATGTCGTTAAACCTGGTGATACA-3’
5’-GGTTTGCTGGTTGCTTCTTATC-3’
srtA (qPCR)

5’-/56-

This study

FAM/AGCAAGCTA/ZEN/AACCTCAGATTCC
GAAAGA/3IABkFQ/-3’
5’-GAACAGGCGAGTAAAGACAATAAG-3’
5’-GGTCCTGGATATACTGGTTCTTT-3’
16S (qPCR)

5’-/56-

[104]

FAM/CCGGCAGTC/ZEN/AACTTA/3IABkFQ/3’
5’-CACCTTCCTCCGGTTTGTCA-3’
5’-CCCTTGAACTTAGTTGCCATCATTC-3’
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Winooski, VT). Commercially available S. aureus Protein A (Thermo Scientific,
Rockford, IL) was used to generate the standard curve.

Flow Cytometry to Measure Surface-Expressed Protein A, FibrinogenBinding Protein and Fibronectin-Binding Protein

One milliliter of log phase bacterial cells were washed and incubated with either
no conjugate (NC, negative control), 2μg/ml of chicken anti-protein A FITC
conjugate (Gallus Immunotech, Cary, NC), 1μg/ml human fibrinogen FITC
conjugate (Zedira GmbH, Darmstadt, Germany) or 1μg/ml bovine fibronectin
HiLyte Fluor TM 488 conjugate (Cytoskeleton Inc., Denver, CO) for 30 min at room
temperature in the dark. Excess conjugate was removed by washing and the
amount of binding determined by measuring fluorescence using an Attune acoustic
focusing cytometer (Applied Biosystems, Foster City, CA) at excitation/emission
wavelengths of 488/519 nm. Data were acquired in linear mode for forward and
side scatter and logarithmic mode for fluorescence. For each sample, 10,000
events were measured.

Statistical Analysis

A one-way ANOVA and multiple comparisons using Tukey’s honest significant
difference were performed to test if there was a significant difference in the
expression of spa and srt among bacterial isolates, and also to determine if there
was a significant difference in the amount of surface-expressed Protein A,
fibrinogen-binding protein and fibronectin-binding protein. Each experiment was
repeated at least three times and a p-value of <0.05 was considered significant.
All analyses were conducted using the IBM SPSS Statistics for Windows, Version
22.0 (IBM Corp, Armonk, NY).
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Results
Wood 46 Expresses Lower Amounts of Cell Wall-Associated Protein A

Flow cytometry using chicken anti-Protein A antibody was performed to determine
the amount of cell wall-associated Protein A. The amount of binding was
normalized against Seattle 1945 which showed maximum binding in this assay
(assigned 100% binding). Wood 46 bound lower amounts of the antibody (about
19%) relative to Seattle 1945. The Δsbi, Δspa and Δsbi-Δspa mutants bound 76%,
27% and 9% of the antibody respectively. In contrast, Cowan 1 and the Newman
WT isolate, both reported to be high producers of Protein A bound 69% and 83%
respectively (Figure 2.1), indicating that Wood 46 may have lower amounts of cell
wall-associated Protein A compared to the positive control strains used in this
study.

Secreted Protein A in Culture Supernatant of Wood 46

S. aureus releases Protein A during the exponential growth phase [41, 42]. To
confirm this in Wood 46, a Protein A-capture ELISA was used to measure the
amount of Protein A secreted into culture supernatant. Both overnight (data not
shown) and log phase culture supernatants were tested. Wood 46 secreted 12.42
ng/ml of Protein A into the culture supernatant compared to Seattle 1945 which
secreted the highest amount of Protein A (22.56ng/ml) during log phase (Figure
2.2). These data indicate that Wood 46 produces and secretes Protein A, although
the amount is lower, although not statistically significant, compared to Seattle 1945
or wild-type Newman isolates.
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Figure 2.1 Cell wall-associated Protein A in S. aureus.
Protein A expressed on the surface of S. aureus strains Cowan1, Seattle 1945
(25923), Wood 46, Newman WT and its corresponding deletion mutants, Δsbi,
Δspa and Δsbi-Δspa, as measured by flow cytometry with chicken anti-Protein A
antibody. The values represent the average from three independent experiments.
(*P<0.05 and **P<0.02 were considered significant).
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Figure 2.2 Production of extracellular Protein A in S. aureus.
The amount of secreted Protein A was measured using an antigen-capture ELISA.
Commercially available Protein A from S.aureus was used to generate the
standard curve. The values represent the average from three independent
experiments. (*P<0.05 was considered significant).
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Gene Sequence Analysis of spa, srtA and Regulatory Region of srtA

It was hypothesized that if the spa gene in Wood 46 harbors a mutation, it may
lead to a truncated or non-functional protein. In order to test this hypothesis, the
spa gene in Wood 46 and other S. aureus isolates was amplified using PCR and
the products were sequenced and analyzed. Results from the PCR and DNA
sequence analysis of the spa gene showed that Wood 46 not only possesses the
full-length spa gene, but also the sequence of the spa gene is in complete
agreement with those from Cowan 1, Seattle 1945 and wild-type Newman (data
not shown). Therefore, mutation in the spa gene was ruled out as the possible
cause for lower expression of Protein A in Wood 46.
Sequence analysis of the srtA gene in Wood 46, however, showed that it has a
12bp deletion at the 3’ end of the gene that results in a four amino acid difference
in the protein compared to S. aureus Cowan 1, Seattle 1945 and wild-type
Newman (Figure 2.3). Also, analysis of the upstream promoter and regulatory
region showed that Wood 46 contains mutations in both the -10 and -35 regions
(Figure 2.4). These mutations likely adversely affect RNA polymerase binding and
transcription as mutations in the upstream promoter and regulatory regions have
been associated with reduced gene expression [127-129].

mRNA Levels of spa and srtA in Wood 46

If the transcription of spa is adversely affected, it could lead to lower expression of
Protein A on the bacterial surface. Reverse transcriptase qPCR was used to
analyze the expression of spa in S. aureus isolates. The results showed that Wood
46 transcribes spa mRNA although the levels were lower compared to
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Figure 2.3 Amino acid composition of Sortase A.
The amino acid sequence of Sortase A in Cowan 1, Seattle 1945, Newman and
Wood 46 were aligned. Amino acids from position 155 to the end of the protein are
shown. Wood 46 contains a 12bp deletion at the 3’ end of the srtA gene that leads
to a corresponding loss of four amino acids at the C-terminus of the protein.

Figure 2.4 Upstream promoter and regulatory region of srtA
Consensus promoter and upstream regulatory sequence from Cowan 1, Seattle
1945 and Newman was aligned with that of Wood 46. The boxes highlight regions
with mutations. The transcription start site ATG is indicated as +1.
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Cowan 1 (assigned as the calibrator for this experiment), Seattle 1945 (0.74 fold)
and wild-type Newman isolate (Figure 2.5). As expected, the Δspa and Δsbi, Δspa
mutants did not produce detectable spa mRNA. This suggests that inefficient spa
transcription was not the reason for low surface expression of Protein A in Wood
46. The spa expression level was normalized against 16S rRNA as the
endogenous control and the results were expressed as fold change in mRNA
levels using the ΔΔCT method. To ensure equal amplification efficiencies of the
target and control genes, four 10-fold serial dilutions of the target RNA were tested.
The efficiencies of both the target gene and the endogenous control were
comparable.
Conversely, the expression level of srtA mRNA in Wood 46 was below the limit of
detection of the assay. Cowan 1 was assigned as the calibrator strain for this
experiment. The expression levels of Seattle 1945 and Newman WT were 0.26
fold and 0.28 fold relative to Cowan 1, while that of the deletion mutants Δsbi, Δspa
and Δsbi,Δspa were 0.14 fold, 1.03 fold and 0.51 fold respectively (Figure 2.6).
Taken together, the results suggest the lack of Sortase A could be responsible for
the deficient anchoring of Protein A in Wood 46.

Wood 46 Expresses Lower Amounts of the LPXTG Motif-Harboring
Fibrinogen-Binding Protein and Fibronectin-Binding Protein
Sortase A is responsible for anchoring proteins with an LPXTG motif on to the
peptidoglycan cell well [62, 64, 66, 124, 130]. If lack of this enzyme is indeed the
reason for low surface density of Protein A in Wood 46, there should be a global
decrease in the expression of all surface proteins that bear the LPXTG motif. In
order to test this hypothesis, two well-studied proteins with LPXTG motifs were
chosen. Fibrinogen-binding protein (Clf A and B) and fibronectin-binding protein
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Figure 2.5 Expression levels of spa in S. aureus
Quantitative real-time PCR was used to measure the amount of spa mRNA in log
phase bacterial cells. Relative gene expression was calculated using the ΔΔCT
method and expressed as fold change. 16S rRNA was used as the endogenous
control. The values represent the average from three independent experiments.
(*P<0.05 was considered significant). ND- not detected.
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Figure 2.6 Expression levels of srtA in S. aureus.
Quantitative real-time PCR was used to measure the amount of srtA mRNA in log
phase bacterial cells. Relative gene expression was calculated using the ΔΔCT
method and expressed as fold change. 16S rRNA was used as the endogenous
control. The values represent the average from three independent experiments.
(*P<0.05 and **P<0.02 were considered significant). ND- not detected.
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(FnBP A and B) are anchored on the bacterial surface and known immune evasion
factors in S. aureus. A binding assay was performed with FITC-labeled human
fibrinogen to detect surface-expressed fibrinogen-binding protein, and HiLyte Fluor
TM

488 conjugated bovine fibronectin to detect surface-expressed fibronectin-

binding protein. Flow cytometry results showed that Wood 46 bound only 0.49%
of labeled fibrinogen on its surface compared to the Δspa isolate which bound the
highest amount of fibrinogen in this study (Figure 2.7). Also, Wood 46 bound only
11.4% of the labeled fibronectin relative to Cowan 1 (considered as 100%) and
Seattle 1945 (31.2%) (Figure 2.8). The Newman isolate and its corresponding
deletion mutants were not tested in the fibronectin-binding assay because they
have truncations in both FnBP A and FnBP B [131]. These data suggest the lack
of Sortase A in Wood 46 likely results in lower amounts of not just Protein A, but
other proteins that bear the LPXTG motif.
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Figure 2.7 Fibrinogen-binding assay.
The amount of Sortase A-anchored, LPXTG-motif containing fibrinogen-binding
protein was measured by flow cytometry using FITC-conjugated fibrinogen. The
percentage binding was determined relative to highest value obtained for that
experiment. The values represent the average from three independent
experiments. (*P<0.05 and **P<0.02 were considered significant).
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Figure 2.8 Fibronectin-binding assay.
The amount of Sortase A-anchored, LPXTG-motif containing fibronectin-binding
protein was measured by flow cytometry using HiLyte Fluor

TM

488-conjugated

fibronectin. The percentage binding was determined relative to highest value
obtained for that experiment. The values represent the average from three
independent experiments. (*P<0.05 and **P<0.02 were considered significant).
(Since the Newman isolate has truncations in both FnBP-A and FnBP-B, it was not
tested in the fibronectin binding assay).
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Discussion
S. aureus produces a number of virulence factors including secreted toxins,
enzymes and cell wall-associated proteins that bind to and interact with host
extracellular matrix [132]. In an in vitro environment, the production of virulence
factors is growth-phase dependent [133]. The secreted proteins are produced
during post-exponential (stationary) phase wheras the cell wall-associated
proteins are predominantly produced during the logarithmic growth phase [134,
135]. Many of the known virulence factors such as Protein A, fibrinogen-binding
proteins like clumping Factors A and B, fibronectin-binding proteins A and B are
synthesized and anchored onto the peptidoglycan cell wall by the transpeptidase
enzyme, Sortase A [66, 124, 130, 136].
The S. aureus isolate Wood 46 has played an important role in studies designed
to examine the biological function of Protein A and its role in pathogenesis and
virulence. There have been contradictory reports on the production, display and
secretion of Protein A [119, 137]. The results have either been ambiguous or
lacked definitive experimental data. Wood 46 has been described as a spanegative and Protein A-deficient strain although there is evidence that Wood 46
expresses low amounts of Protein A on its surface as evidenced by its ability to
bind low amounts of IgG [119, 138]. It is also reported that Wood 46 secretes small
amounts Protein A into the culture supernatant during exponential growth phase
[118, 119]. Recently, several mutant strains have replaced Wood 46 as the
preferred choice for negative control in both in vitro and in vivo studies. However,
the mechanism for low expression of Protein A on the surface of Wood 46 had not
been previously investigated.
Cell wall-associated Protein A binds to IgG via its Fc region, thereby preventing it
from opsonization and phagocytosis [36]. In this study, it was observed that Wood
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46 had a lower density of Protein A on its surface and secreted less Protein A
compared to the Cowan 1, Seattle 1945 or Newman isolates. It was observed that
even the Δspa isolate bound some anti-Protein A antibody. This could be due to
the ability of the antibody to react with other immunoglobulin-binding proteins on
the surface of the bacterium. Secreted Protein A functions as a superantigen (SAg)
[48]. It binds to VH3-clan B-cell receptors and limits their abilities to produce
antibody. Also, marginal zone B-cells and B1-cells undergo apoptosis upon
exposure to Protein A [44-48, 108]. There have been reports of secreted Protein
A in Wood 46 activating human B-cells in a mechanism that is different from that
seen in Cowan 1 [139]. Therefore, it is important to consider the toxic effects of
secreted Protein A, if Wood 46 is used as a control in animal models to test vaccine
efficacy.
Conventional PCR and sequencing showed that Wood 46 possesses the spa gene
with a complete open reading frame. The gene sequence is identical to that of
Seattle 1945, Cowan 1 and Newman. qPCR for spa expression showed that Wood
46 does transcribe spa mRNA but at lower amounts compared to that of Cowan 1,
Seattle 1945 and Newman isolates. Because this did not explain the low surface
levels of Protein A, the transpeptidase enzyme Sortase A responsible for
anchoring surface proteins on the peptidoglycan cell wall, was examined.
Conventional PCR with srtA-specific primers showed that Wood 46 possesses the
srtA gene with a complete open reading frame. However, it harbors a 12bp deletion
at the 3’-end of the gene resulting in a corresponding loss of four amino acids at
the N-terminus of the protein sequence. Further analysis of the upstream region of
the srt A gene shows mutations in the -10 and -35 regions of the promoter and
regulatory that would be expected to adversely affect binding of RNA polymerase
and transcription. The functional effects of these mutations are yet to be evaluated
and may be pursued at a later stage.

Promoter site mutations have been

associated with impaired transcription and in turn affect protein expression [12776

129, 140-143]. These mutations could affect the expression of srtA which in turn
may be responsible for the low surface density of Protein A. If this is true, there
should be a decrease in the expression of other surface proteins that harbor the
LPXTG motif. This was confirmed by examining the surface expression of two
known LPXTG proteins, fibrinogen-binding protein (Clf A and Clf B) and
fibronectin-binding protein (FnBP A and FnBP B). Both these proteins in S. aureus
are virulence factors similar to Protein A [62, 66, 108, 124, 125, 144]. Wood 46
expressed very low amounts of both fibrinogen-binding protein and fibronectinbinding protein on its surface suggesting that it may express lower amounts of all
surface proteins that have an LPXTG motif. The complete coding sequence of the
Wood 46 srtA gene along with the upstream promoter and regulatory region has
been deposited in GenBank (accession number: KY514391). The whole genome
sequence of Wood 46 has been determined and deposited in GenBank (accession
number: MTFQ00000000, version MTFQ00000000.1). This could provide a wealth
of information about other immunoglobulin- binding proteins with or without an
LPXTG motif. It will also help identify novel genes whose products may be involved
in immune evasion. Sequence information about promoters and regulatory
elements of virulence genes could help explain why some strains of
S. aureus are innately less virulent compared to other highly virulent strains.
In conclusion, the results from this study suggest that defective expression of srtA
in Wood 46 accounts for the failure of Protein A anchoring to its surface with the
majority of the Protein A being secreted. This may be accompanied by deficient
anchoring of all LPXTG bearing surface proteins. The Wood 46 promoter at both
the -10 and -35 regions contained mutations compared to the control strains used
in this study. Promotors that vary from consensus sequences generally are
associated with decreased gene expression [140, 141, 143]. Understanding the
nature of surface protein expression and its role in virulence is crucial towards
successful vaccine development against S. aureus
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CHAPTER 3.
Complete Genome Sequence of the Staphylococcus aureus
Strain Wood 46
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Here,

we

report

the

first

complete

genome

sequence

of

the

Staphylococcus aureus strain, Wood 46. Wood 46 has played an important
role in understanding the virulence and pathogenesis of S. aureus
infections. This report will assist efforts in vaccine development against
MRSA infections.
Staphylococcus aureus is a Gram-positive opportunistic pathogen that infects both
humans and animals. It causes skin and soft tissue infections, and is also
associated with septic arthritis, pneumonia, post-surgical and implant infections,
osteomyelitis, septicemia and toxic shock syndrome [145, 146]. Methicillinresistant S. aureus (MRSA) is an important concern in hospitals (HA-MRSA),
communities (CA-MRSA) and among livestock (LA-MRSA) [82, 146]. New vaccine
discovery efforts rely on understanding the role of surface and/or secreted proteins
in

pathogenesis

and

infection

[44,

147].

The

S.

aureus

Wood 46 strain was reported to be Protein A-deficient and assumed to be spa
negative [148]. It has also been shown to have reduced virulence in animal models
of S. aureus infection [31, 107, 117-122, 149]. To date, the reason for reduced
virulence and Protein A expression in the Wood 46 strain remains unknown. Whole
genome sequence of this strain could provide insights into the genes, promoters
and regulatory regions involved in pathogenesis and virulence. This in turn could
help understand the role of specific virulence factors during infection and identify
novel vaccine targets and/or develop novel strategies to combat MRSA infections.
The S. aureus Wood 46 strain was sourced from the American Type Culture
Collection (ATCC 10832). DNA was sequenced using Illumina MiSeq (Illumina,
Inc., USA). De novo assemblies were individually produced and merged using
Geneious (version 9.1.6) and CLC Genomics Workbench (version 9.0)
(http://www.qiagenbioinformatics.com). Automated annotation was performed
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using

the

NCBI

Prokaryotic

Genome

Annotation

Pipeline

(http://ncbi.nlm.nih.gov/genome/annotation_prok).
A total of 3,985,114 high-quality reads resulted in >180-fold overall coverage. The
genome is 2,824,597 bp with a 32.8% GC content. The number of predicted coding
sequences (CDS) and genes (RNAs) were 2806 and 73 respectively. The Wood
46 genome shared 98%-99% identity with other published S. aureus genomes.
The bacterium is susceptible to amoxicillin/clavulanic acid, cefoxitin, cephalothin,
chloramphenicol, clindamycin, erythromycin, gentamicin, marbofloxacin, oxacillin,
tetracycline and trimethroprim/sulfa, and resistant to ampicillin and cefpodoxime
[150].
Nucleotide sequence accession number: The Whole Genome Shotgun project
of the S. aureus strain Wood 46 has been deposited at DDBJ/ENA/GenBank
GenBank under the accession number MTFQ00000000. The version described in
this paper is MTFQ00000000.1.
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Abstract
Staphylococcus pseudintermedius is a Gram-positive coccus and a common
opportunistic pathogen in dogs. It causes skin and soft tissue infections, and is the
most frequent cause of canine pyoderma. In the past few years, this organism has
developed widespread resistance to methicillin. Many of the methicillin resistant S.
pseudintermedius (MRSP) isolates are also multidrug resistant. The emergence of
antimicrobial resistance has spurred the search for prophylactic methods for the
control of these bacteria. Vaccine development, however, requires a deeper look
into the surface properties of varying strains of S. pseudintermedius. S.
pseudintermedius is known to produce a wide variety of virulence factors. Some
of these are surface-associated while others are secreted.
The purpose of this study was to analyze the whole secretome (secreted proteins)
and surface-associated proteins in S. pseudintermedius by Mass Spectrometry
(MS) in an effort to identify potential vaccine candidates. Three isolates
representing the major clonal populations of S. pseudintermedius in the United
States and Europe- 06-3228 (ST68), 08-1661 (ST71) and NA45 (ST84) - were
selected for this study. The specific objectives of this study were: (a) to analyze
the entire bacterial secretome (b) to identify secreted immunoglobulin-binding (Igbinding) proteins and (c) to identify proteins accessible on the surface of the
bacteria.
The secretome, Ig-binding proteins and trypsin-treated proteins were compared
among the three isolates using their respective genomes as reference databases.
Orthologous proteins among the three isolates were identified and from this group,
proteins common to all three isolates were further analyzed to determine if they
were good vaccine candidates.
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Introduction
S. pseudintermedius is an opportunistic pathogen residing on the skin and mucosa
of dogs and is frequently isolated from the nares, mouth, pharynx, forehead, groin
and anus of healthy dogs and cats [7]. When the host immune system is
suppressed or weakened, or if there is a breach in the external skin barrier, it can
cause severe skin and soft tissue infections. It is the leading cause of clinical
infections in dogs suffering from atopic dermatitis and is implicated in the
pathogenesis of canine pyoderma [7, 8, 29]. Recently, the emergence of methicillin
resistance and multidrug resistance in S. pseudintermedius has complicated
treatment. This is due to limited treatment options and the often long duration and
repeated treatments that are required to clear infection, sometimes extending over
3-4 weeks along with a topical treatment [7, 8, 29, 81]. Such prolonged therapies
may result in emergence of resistant bacteria. Once selected, this resistance may
be horizontally transferred to other bacteria which may include human pathogens.
Also, S. pseudintermedius has zoonotic potential and in rare cases has been
reported to cause severe infections in humans, the most common route being dog
bite wounds [7]. Therefore, there is an urgent need for effective methods to prevent
and control S. pseudintermedius infections in dogs.
The development of a successful vaccine against S. pseudintermedius requires a
thorough understanding of the ecology and epidemiology of the bacteria,
knowledge of bacterial and host factors involved in pathogenesis, and the nature
of immune response. In the past, crude preparations based on S. aureus phage
lysate or S. pseudintermedius autogenous bacterin had shown promise as
adjunctive therapies to treat pyoderma [8, 15]. An efficacious vaccine administered
either prophylactically or after the onset of an infection may be the most effective
way of combating canine pyoderma.

85

Cell-wall associated (CWA) proteins produced by Gram-positive pathogens play a
crucial rule in the pathogenesis of infection [15]. Surface-exposed and secreted
proteins are more likely to interact with the host immune system. Several studies
with S. aureus have indicated that CWA proteins represent promising targets for
immunotherapeutic and vaccine design [151] . Little is known about the
pathogenesis of S. pseudintermedius. However, S. pseudintermedius produces a
number of virulence factors, including some which are functionally similar to those
produced by S. aureus [22]. These include enzymes such as coagulase,
proteases, thermonuclease, and toxins including hemolysins, exfoliative toxins and
enterotoxins. S. pseudintermedius produces several CWA proteins that closely
resemble those of S.aureus, including extracellular matrix (ECM) proteins
fibrinogen-binding proteins, fibronectin-binding proteins, and cytokeratin [15, 22,
29, 151]. Protein A encoded by the spa gene in S. aureus, one of the most potent
immune evasion factors, also has a homologue in S. pseudintermedius designated
as SpsQ (spa1) [15].

Along with Protein A, another immunoglobulin-binding

protein, Sbi, in S. aureus, designated SpsK in S. pseudintermedius also functions
as an immune evasion factor. Both these proteins are found abundantly on the
bacterial surface but are not good vaccine candidates because of their toxicity and
B-cell super-antigen activity [151].
Vaccine studies with S. aureus suggest that multicomponent vaccine would be
advantageous over killed or attenuated whole bacterial vaccine [152, 153]. Recent
advancements in genome sequencing have made it possible to identify novel
vaccine targets using reverse vaccinology. This technology has successfully been
employed in S. aureus and vaccine development based on surface-exposed and
secreted proteins have seen success in mouse models [154, 155]. The other
important consideration during vaccine development is identification of targets
conserved among a variety of strains. The identification of orthologous groups in
prokaryotic

genomes

allows

cross-referencing

of

genes

from

multiple
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species/strains and facilitates genome annotation. Further, it makes possible the
classification of protein families, bacterial evolution and identification of novel
targets for antimicrobial drug development [156-159]. Mass spectrometry has also
emerged as a powerful and efficient tool for analyzing proteins to identify
biomarkers and vaccine targets [160].
In the present study, mass spectrometry was used to identify the surface proteins
and secreted proteins from three strains of S. pseudintermedius; 06-3228 (ST68),
08-1661 (ST71) and NA45 (ST 84) which are representatives of the major clonal
populations in the United States and Europe. Comparative analysis of the surface
proteins and secreted proteins among these isolates could provide a wealth of
information about strain similarities and differences, and identify novel proteins that
could serve as vaccine targets.

Materials and Methods
Bacterial Strains and Growth Conditions

S. pseudintermedius clinical isolates 06-3228 (ST68), 08-1661 (ST71) and NA 45
(ST 84) were used for this study. The isolates were obtained from the Clinical
Bacteriology Lab at the Veterinary Medical Center, University of Tennessee,
Knoxville. Bacterial colonies from blood agar plates were inoculated into 5ml of
sterile Trypticase Soy Broth (TSB) (BD Biosciences, San Jose, CA) and incubated
overnight at 37°C with shaking at 225rpm (Excella E24 Incubator Shaker, New
Brunswick Scientific). Fifty microliters of overnight culture were inoculated into 5ml
of fresh, sterile TSB to initiate log-phase bacterial cultures. The bacteria were
grown at 37°C with shaking at 225rpm until an optical density of OD

600

= 0.4-0.6

was reached.
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Preparation of Whole Secretome

Log phase bacterial cultures were centrifuged at 10,000xg for 30 minutes at 4°C
(Sorvall RC-5C Plus Superspeed Centrifuge). Without disturbing the bacterial
pellet, the supernatant was collected and passed through a 0.45μm filter
(Whatman, GE Healthcare Lifesciences, Pittsburgh, PA). The filtrate was
concentrated using an Amicon® Ultra-4 centrifugal filter (EMD Millipore Corp.,
Billerica, MA) and stored at -20°C until further analysis.

Purification of Immunoglobulin-Binding Proteins from Bacterial Culture
Supernatants

Log phase bacterial cultures were centrifuged at 10,000xg for 30 minutes at 4°C.
The supernatant was passed through an IgG-sepharose column (GE Healthcare
Lifesciences, Pittsburgh, PA). Briefly, the column was equilibrated with five bed
volumes of binding buffer containing 50 mM Tris, 2.7 mM potassium chloride and
0.137 M NaCl pH 8.0. The bacterial supernatant was added to the column to allow
attachment of IgG binding proteins. Unbound proteins were washed off with 15
bed volumes of binding buffer. The bound proteins were eluted in 0.1-0.2 M
Glycine/HCl pH 2.5-3.0. The pH of the elution fraction was adjusted to 7.0 using
0.5M Tris and stored at -20°C until further analysis.

Purification of Trypsin-Treated Surface Proteins

Log phase bacterial cultures were centrifuged at 4,200xg for 3min and washed
three times with PBS. The pellet was suspended in 1ml digestion buffer (0.6M
sucrose buffered with 50mM Tris, pH 7.5). Two hundred microgram of porcine
trypsin (Sigma-Aldrich, St.Louis, MO) was added and the cells were digested for 1
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hour at 37°C. Protease inhibitor cocktail set IV (Calbiochem, EMD Millipore Corp,
Temecula, CA) was then added to the mixture at a final concentration of 0.1μg/ml.
The supernatant containing tryptic peptides was stored at -20°C until further
analysis.

Biotin Labeling of Surface Proteins

Log phase bacterial cells were harvested by centrifugation at 10,000xg for 1min
and washed twice with ice-cold phosphate buffered saline (PBS) pH 8.0. One
hundred microliters of 10mM EZ-Link Sulfo-NHS-LC-Biotin reagent (Thermo
Scientific, Waltham, MA) per 1ml of cell suspension was added and incubated for
30min at room temperature. The cells were washed three times with PBS and
100mM glycine was added to quench and remove excess biotin. The biotinlabeled bacteria were stored in aliquots at -20°C until further use. The biotinlabeled proteins were digested with trypsin as described previously and were
stored at -20°C until further use.

Purification of Biotin-Labeled Surface Proteins Using Monomeric Avidin

Biotin-labeled surface proteins were purified using a monomeric avidin column
(Pierce Monomeric Avidin Kit, Thermo Scientific, Waltham, MA) as per
manufacturer’s protocol. Briefly, the monomeric avidin column was washed with
8ml of PBS followed by the addition of 6ml of biotin blocking buffer to block any
non-reversible biotin binding sites. The excess biotin was removed from the
reversible binding sites by addition of 12ml of regeneration buffer. The biotinlabeled, trypsin-cleaved proteins were loaded onto the column. Unbound proteins
were washed off with PBS. The bound proteins were eluted using elution buffer in
6 X 2ml fractions. The eluates were stored at -20°C until further use.
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LC-MS/MS Analysis

Samples interrogating S. pseudintermedius supernatant and surface-associated
proteins were prepared for shotgun liquid crystallography-mass spectrometry (LCMS/MS) analysis. Trypticase soy broth (media alone) and bacterial culture
supernatant passed through control Sepharose beads (without IgG) served as
controls. Prior to protein denaturation with sodium dodecyl sulfate (SDS), samples
were concentrated / solvent exchanged on molecular weight cut-off (MWCO) spin
filters (Vivaspin, GE Healthcare Lifesciences, Pittsburgh, PA) that retain
proteins/polypeptides > 5kDa in size (~ 50 amino acids or larger). Retained
proteins were then re-suspended in 4% SDS, 100mM Tris-HCl, 5mM dithiothreitol
(DTT), transferred to microcentrifuge tube, and incubated at 95°C for 5min.
Iodoacetamide was then added to a final concentration of 15mM and samples
incubated for 20 min in the dark at room temperature. Denatured and reduced
proteins were then digested to peptides with 2μg of proteomics-grade porcine
trypsin (Sigma-Aldrich, St.Louis, MO) for 4 hours. Following digestion, peptide
samples were adjusted with 200mM NaCl-0.1% formic acid and passed through a
10kDa MWCO Vivaspin2 spin filter to collect appropriately sized tryptic peptides
for LC-MS/MS analysis.
With the aid of a pressure cell, peptides were loaded onto a biphasic MudPIT back
column containing both strong-cation exchange and reversed-phase (RP) resins5u Luna or 5u Kinetex, respectively (Phenomenex, Torrance, CA) and separated
as previously detailed [161]. Briefly, loaded samples were washed offline then
placed in line with an in-house pulled nanospray emitter packed with 15cm of RP
resin. Peptides were then separated and analyzed with either a 2-step MudPIT LCMS/MS protocol (salt cuts of 50mM and 50mM ammonium acetate) over a 4-hr
period (supernatant samples) or a 1-step protocol (500mM ammonium acetate)
over a 2-hr period (surface proteins and pulldown samples). All samples were
measured with a hybrid LTQ XL-Orbitrap (Thermo Scientific, Waltham, MA) mass
90

spectrometer (MS) as follows: data-dependent acquisition, 1 full scan followed by
10 MS/MS scans. Orbitrap mass analyzer was set to 15K resolution, LTQ isolation
window = 2.2 m/z, monoisotopic precursor selection, dynamic exclusion window,
duration, and max = 3 m/z, 60s (30s for supernatant samples), and 500
respectively. The immunogenicity of peptides was predicted using the POPI v.2.0
web server.

Results
LC MS/MS Data Analysis

LC-MS/MS spectra were searched against sample-specific proteome databases
[103] concatenated with common protein contaminants using MyriMatch v.2.2
[162]. Peptide spectrum matches (PSM) were filtered and assembled to proteins
using IDPicker v.3.0 [163] with false-discovery rates, as assessed by evaluating
MS/MS spectra that matched to reversed decoy sequences, controlled at < 1% at
the peptide-level. Protein calls required two distinct peptides at a minimum.
Peptide intensities were assessed by chromatographic area-under-the-curve
(AUC) using IDPicker’s embedded spectra/label-free quantification option and
protein abundances derived via summation of constituent peptides intensities. To
qualitatively

compare

the

proteins

identified

across

each

strain

of

S. pseudintermedius, OrthoMCL (OrthoMCL Database, Version 5.0) [164-166]
was employed to identify orthologous protein sequences. Identified protein data
for each specific S. pseudintermedius sequence type were then re-cast into their
orthologous groups and compared across all sample types to identify proteins
common to all three pathogenic strains – with special emphasis on those that are
surface-associated and/or secreted. To help winnow down the list of potential
secreted and surface-bound antigen targets, PSORTb v.3.0 [167] was used to
assign subcellular location to each identified protein.
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Identification of Surface Proteins, IgG-Binding Proteins and Extracellular
(Secreted) Proteins by Mass Spectrometry

Using the analysis method described above, a total of 580 proteins were identified
in the isolate 06-3228 (ST68), 596 in 08-1661 (ST71) and 542 in NA45 (ST84).
The number of proteins in each fraction is listed in Table 4.1 and the percentage
of proteins in each fraction for individual isolates, 06-3228 (Figure 4.1), 08-1661
(Figure 4.2) and NA45 (Figure 4.3) is depicted.

Orthologous Proteins in 06-3228, 08-1661 and NA45

In order to narrow down the spectrum of proteins for analysis across all three
sequence types, orthologous protein prediction was performed using the webbased tool OrthoMCL. A total of 364 predicted orthologous proteins were identified
across all three sequence types. Excluding proteins that were classified as
cytoplasmic in origin, there were 72 proteins predicted to be either secreted
(17/72), cell wall-associated (10/72) or of unknown cellular location (45/72) across
all three sequence types. The percentage of orthologous proteins based on their
location is shown in Figure 4.4. Isolate 06-3228 had at least 10 proteins that were
predicted to be cell wall-associated and 16 extracellular proteins. Isolate 08-1661
had 10 proteins predicted to be cell wall-associated and 17 extracellular proteins
while isolate NA45 had 9 predicted cell wall-associated proteins and 14
extracellular proteins. From this list, eight proteins common to all three isolates
were identified that could potentially function as antigens. This includes: predicted
cell wall-anchored protein SasF (LPXAG motif), beta-hemolysin, gammahemolysin component B, secretory antigen precursor, SsaA, fibronectin-binding
protein FnbB, oligopeptide ABC transporter, virulence-associated cell wallanchored protein SasH (LPXTG motif) and exotoxin 15.
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Table 4.1 Total number of predicted proteins in each of the fractions
analyzed by mass spectrometry for isolates 06-3228, 08-1661 and NA45
Isolate

Sequence Secreted
Type

Proteins

IgG-

Surface

Binding

Proteins

Proteins
06-

Biotinylated Total
Surface
Proteins

ST68

202

38

234

106

580

ST71

237

26

274

59

596

ST84

162

66

260

54

542

3228
081661
NA45
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Figure 4.1 Percentage of proteins predicted in each fraction for isolate 063228
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Figure 4.2 Percentage of proteins predicted in each fraction for isolate 081661
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Figure 4.3 Percentage of proteins predicted in each fraction for isolate NA45
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Figure 4.4 Percentage of predicted orthologous proteins across all three
isolates.
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Additionally, three proteins, putative peptidoglycan bound protein (LPXTG) motif
Lmo1799 homolog, immunodominant staphylococcal antigen A precursor and zinc
metalloproteinase precursor/aureolysin) that were identified only in isolates 083228 and 08-1661 could also be potential antigenic targets (Table 4.2).

Identification of Peptides with High Immunogenic Potential

Peptide sequences from the eight proteins were tested for their immunogenicity
using the online immunogenicity prediction tool POPI v.2.0. Sequences
corresponding to SasF, SsaA, SasH, FnBP and exotoxin 15 are predicted to be
good vaccine candidates. Taken together, the results suggest that Mass
Spectrometry, along with orthologous protein prediction could be a good strategy
to scan for potential vaccine targets in S. pseudintermedius.
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Table 4.2 List of orthologous proteins identified across all three isolates with
their predicted cellular location
Predicted Protein

Cellular
Location

All

3 Predicted

cell-wall-anchored

protein Cell wall

sequence

SasF (LPXAG motif)

types

Virulence-associated cell-wall-anchored Cell wall
protein SasH (LPXTG motif)

ST68
ST 71

Fibronectin binding protein FnbB

Cell wall

Oligopeptide ABC transporter

Cell wall

Beta-hemolysin

Extracellular

Gamma-hemolysin component B

Extracellular

Secretory antigen precursor SsaA

Extracellular

Exotoxin 15

Extracellular

and Putative peptidoglycan bound protein Cell wall
(LPXTG motif) Lmo1799 homolog
Immunodominant staphylococcal antigen Extracellular
A precursor
Zinc

metalloproteinase Extracellular

precursor/aureolysin
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Discussion
The increasing prevalence of methicillin resistance and multidrug resistance
among staphylococci has given rise to ‘superbugs’ that can no longer be treated
with conventional antibiotics. This is especially difficult in veterinary medicine
where the number of antibiotic choices available to treat S. pseudintermedius
infections is limited. Therefore, it has become important to seek alternative
treatment strategies, such as preventative or therapeutic vaccines. In the past,
attempts to generate S. aureus vaccines based on whole-cell determinants and/or
virulence factors have failed to induce protective immunity in humans, although
they have demonstrated promising results in animal models [44, 84-86, 168, 169].
A multivalent vaccine is considered the best strategy for vaccine development
against S. aureus [112, 153, 169-171]. A successful vaccine against
staphylococcal infections should be able to elicit three major immune responses
(a) humoral immune response i.e., antibodies to directly inhibit bacterial viability
and/or toxicity (b) antibodies to mediate opsonophagocytosis and

(c) a cell-

mediated T-helper 1 (Th1)/Th17 response. Identifying novel vaccine candidates
requires extensive analysis of the proteome of S. pseudintermedius. Surface
proteins, particularly cell wall-associated proteins and secreted proteins are most
likely to come in contact with the host, and therefore contribute to the virulence
and pathogenesis. Keeping these factors in mind, the present study analyzed the
secretome and surface proteins in three distinct isolates, 06-3228 (ST68), 08-1661
(ST71) and NA45 (ST84) of S. pseudintermedius by mass spectrometry to identify
novel vaccine targets. Bannoehr et al., had employed a combination of genomic
and

proteomic

approach

to

analyze

the

surface

proteins

in

the

S.

pseudintermedius strain ED99 [15]. They were successful in identifying 60 surface
proteins, including those involved in adhesion.
In the present study, the secretome and surface-associated proteins in three
different S. pseudintermedius isolates was analyzed by mass spectrometry. LC100

MS/MS analysis of surface-associated/exposed supernatant and proteins
expressed by S. pseudintermedius sequence types identified a total of 364
orthologous proteins across all sample types. As revealed by PSORT, a large
majority of these proteins were cytoplasmic in origin and were largely identified in
the supernatant proteomes of each subspecies – a finding that often results from
natural and unavoidable cell lysis over the course of organism growth. These
cytoplasmic “contaminants” are known to be abundant and are generally involved
in central carbon metabolism and organism biogenesis. As these proteins are
irrelevant to this current study, only those proteins classified a non-cytoplasmic in
origin, i.e. those that are cell wall-associated, membrane-associated, extracellular
or unknown/unclassified were the focus of this study. When confining our view to
only these non-cytoplasmic proteins, only 72 proteins remained. As the goal of this
study was to identify secreted or surface-bound protein antigen targets for vaccine
development against pathogenic (MRSP) strains of S. pseudintermedius, these 72
proteins were analyzed in the context of the various enrichment strategies
discussed above with particular attention paid to those that were surface-exposed
and/or secreted, found across all three sequence-types. Eight candidate proteins
were identified that could serve as viable antigen targets. These peptides are as
yet to be tested for their immunogenic potential. Proteins that were annotated as
hypothetical or those predicted with an unknown cellular location were excluded
from this study. Further characterization of these hypothetical proteins is required
to determine if any of them are good vaccine candidates.
Using a combination of mass spectrometry and orthologous protein prediction, it
was possible to identify novel antigenic targets in three S. pseudintermedius
isolates representing three distinct sequence types. Using the same strategy, it is
possible to determine if all clinically relevant S. pseudintermedius strains express
these proteins in high frequency which will further aid in the development of a
multicomponent vaccine against S. pseudintermedius infections.
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CHAPTER 5.
Identification of Staphylococcus pseudintermedius Sortase A
Inhibitors
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Abstract
Conventional antibiotic-based therapies against S. pseudintermedius infections
have failed in recent years, due to the increased prevalence of methicillin
resistance and multidrug resistance. Therefore, alternate strategies for treatment
have to be explored. Anti-infective therapy based on sortase inhibition holds
potential to address this shortcoming. Sortase A (SrtA) is a transpeptidase,
commonly produced by Gram-positive bacteria, that recognizes proteins with a Cterminal LPXTG motif and anchors them on the peptidoglycan cell wall. SrtA
substrates include numerous virulence factors and proteins that may overcome the
host immune response including Protein A, fibrinogen binging proteins and
fibronectin binding proteins.
In the present study, a srtA gene from S. pseudintermedius was synthesized,
inserted into an expression vector and expressed in E.coli. A commercially
available synthetic substrate for SrtA, Abz-LPETG-K(Dnp)-NH2, was used to
assess the function of the recombinant enzyme. Using molecular dynamic
simulations, a 3-D homology model of SrtA was created to screen a library of
compounds from drug databases for potential inhibitors. From the predicted top
twenty most active inhibitors, ten were selected and tested for their ability to inhibit
sortase in-vitro. Four out of ten compounds showed ~50% inhibition of
recombinant SrtA activity. These compounds were further evaluated for their ability
to inhibit SrtA in bacterial culture. The results indicate the possibility of SrtA
inhibition as a potential therapeutic strategy in the treatment of staphylococcal
infection in both humans and animals.
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Introduction
S. pseudintermedius is a skin and mucous membrane commensal of dogs and is
the organism most frequently associated with atopic dermatitis and wound
infections in dogs. It is also implicated in the pathogenesis of canine pyoderma [7,
8]. In the past, antimicrobial agents have been used to successfully control
S. pseudintermedius infections. However, in recent years, there has been an
increased prevalence of methicillin resistance and multidrug resistance among
S. pseudintermedius isolates [5, 7, 80, 95, 98, 172]. This has made treatment of
infection difficult due to the limited number of antimicrobial agents used in
veterinary medicine [173]. Therefore, there is an urgent need for the development
of

non-antibiotic

based

treatment

strategies

to

combat

S. pseudintermedius infections.
Surface proteins in S. aureus harboring a C-terminal sorting signal with an LPXTG
motif are covalently attached onto the peptidoglycan cell wall by the enzyme SrtA
which is encoded by the srtA gene [62, 69]. This 618bp gene encodes a protein of
206 amino acids with a molecular weight of 23.59kDa. The enzyme is a cysteine
transpeptidase that recognizes the conserved LPXTG motif in surface proteins and
specifically cleaves between the threonine (T) and glycine (G) residues. The active
site cysteine of SrtA forms an acyl enzyme intermediate that is relieved by the
nucleophilic attack of the amino group of the pentaglycine cross bridge in
peptidoglycan synthesis precursors. The N-terminus of the enzyme is located in
the cytoplasm while the C-terminal enzymatic region is located across the plasma
membrane (type II membrane topology) [62]. His120, Cys184 and Arg197 form the
catalytic triad of the enzyme and are found to be conserved among sortases in S.
aureus [62, 68]. Surface proteins attached to peptidoglycan precursors are then
incorporated into the bacterial cell wall and displayed on the surface [58, 62, 63,
65, 66, 68, 70, 124]. There are at least 17-21 surface proteins in S. aureus that
harbor the LPXTG motif. Most of these proteins are involved in virulence and
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pathogenesis [62, 124]. SrtA is essential for the functional assembly of all surface
proteins harboring an LPXTG motif, and therefore plays a crucial role in the
pathogenesis

of

S.

aureus

infections.

S. aureus mutants that do not have a functional srtA gene fail to assemble surface
proteins on to the peptidoglycan cell wall. Also, they are unable to form abscess
lesions in organ tissues or cause lethal bacteremia in mice models of S. aureus
infections [57]. Therefore, inhibition of SrtA could result in defective display of all
the proteins harboring the LPXTG motif and render the organism less virulent.
SrtA inhibitors, therefore, may be useful as anti-infective agents particularly in
cases where there is methicillin resistance and multidrug resistance, and disrupt
the pathogenesis of bacterial infections without affecting microbial viability [57, 70,
174]. The earliest described inhibitors of SrtA include methane-thiosulfonates such
as MTSET, and p-hydroxymercuribenzoic acid. All these compounds interact with
Cys184 and render the enzyme inactive [62]. Other natural or chemical compounds
have also been examined for their abilities to inhibit SrtA [62, 175]. Although
identification of inhibitors for SrtA has been ongoing for several years, it has gained
momentum in the last decade due to the advancements in genomics and
proteomics [56].
SrtA in S. pseudintermedius has not been previously examined. In this study, the
srtA gene in S. pseudintermedius was identified, cloned and expressed in E. coli.
Molecular dynamic (MD) simulation using the bioinformatics tool MOE
(Mathematical Operating Environment) was used to generate a 3-D homology
model of S. pseudintermedius SrtA using the existing 3-D model of S. aureus SrtA.
After identifying the active site of S. pseudintermedius SrtA, scaffold hopping and
molecular docking were combined to virtually screen the drug databases NCI
(National Cancer Institute) and Zinc to identify potential inhibitors of S.
pseudintermedius SrtA. Ten potential inhibitors were identified and purchased
from NCI. Of these ten compounds, four inhibited recombinant SrtA in an in vitro
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functional assay using a synthetic SrtA substrate Abz/DNP (Abz-LPETG-K(Dnp)NH2 by at least 50%. These inhibitors were further tested for their ability to inhibit
SrtA in actively growing bacterial cultures. One of the compounds, 1847, showed
at least 50% inhibition of SrtA in actively growing bacterial cultures, suggesting the
possibility

of

SrtA

inhibition

as

an

anti-infective

therapy

against

S.

pseudintermedius infection.

Materials and Methods
Identification of the srtA gene in S. pseudintermedius

Whole genome sequences of several S. pseudintermedius isolates representing
the major clonal populations in the United States and Europe were available for
analysis [103]. The srtA gene from these isolates was identified by a combination
of BLAST (using the S. aureus srtA gene as reference) and conserved domain
search. Multiple sequence alignment (MSA) of the srtA gene from various isolates
was performed to generate a consensus sequence. This sequence was used to
design primers for conventional and quantitative real-time PCR (qPCR) assays.

Bacterial Strains and Growth Conditions

S. pseudintermedius clinical isolates (Table 5.1) were selected based on their
multilocus sequence types [6]. Bacteria from blood agar plates were used to
inoculate trypticase soy broth (TSB, Becton Dickinson, Franklin Lakes, NJ) and
were grown at 37°C overnight with shaking at 225rpm. After an overnight
incubation, 50µl of broth culture were inoculated into 5ml of sterile TSB and
incubated for 3hr at 37°C with shaking to obtain log phase cultures (OD600 = 0.40.6) which were used for all experiments.
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Table 5.1 Bacterial isolates used in this study along with their sequence type
and methicillin resistance profile
Strain

Sequence Type

Methicillin
Resistance

06 3228

ST68

R

08 1294

ST68

R

08 521a

ST68

R

E140

ST71

R

08 1661

ST71

R

NA16

ST71

R

NA12

ST64

R

NA45

ST118

R

KM 241

ST73

S

ED99

ST25

S
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DNA and RNA Extraction for Conventional and Real-Time PCR

Bacterial DNA was extracted from overnight cultures using a commercial kit
(MoBio Ultra Clean DNA Isolation Kit, MoBio, Carlsbad, CA) according to the
manufacturer’s protocol. PCR for srtA gene was performed using the following
primers.

SP

sortase

fwd:

5’-ACTGCGATAAACAGTAACCACTA-3’

and

SP sortase rev: 5’-CGCTCTCCAACACCATTAAC-3’. The following cycling
conditions were performed: initial denaturation at 95°C for 90s followed by 30
cycles of annealing at 55°C for 30s and extension at 72°C for 1min, and a final
extension at 72°C for 5min. PCR products were sequenced (The University of
Tennessee, Genomics Core Facility), aligned, and compared using Geneious
7.1.7.0 (Biomatters, Auckland, New Zealand).
Total RNA was extracted from log phase bacterial cultures using a commercial kit
(MoBio Ultra Clean RNA Isolation kit, MoBio, Carlsbad, CA) according to the
manufacturer’s protocol.

Quantitative Real-Time PCR (qPCR) for srtA was

performed using the TaqMan RNA-to-CT 1-Step kit on an ABI StepOne PCR
System (Applied Biosystems, Foster City, CA) using the following primer-probe
set. Probe: 5’-/56-FAM/TCGCTATTG/ZEN/CGGGACATACGAATT/3IABkFQ/-3’,
Primer

1:

5’-GGATGAATCACTCAAAGACC-3’

and

Primer

2:

5’-CGCTTTGCTTAACTCTGTAA-3’. The following cycling conditions were
performed: 48°C for 30min, 95°C for 10min, 95°C for 15s, 60°C for 1min (40
cycles). qPCR data were analyzed by the ΔΔCT method and normalized against
16S rRNA as the endogenous control as previously described [104].
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SrtA Expression and Purification

A synthetic srtA gene for S. pseudintermedius Sortase A with a 6X-His tag at the
3’ end was designed, codon optimized for expression in E. coli, synthesized and
inserted into the expression vector pET11a (GenScript Inc., Piscataway, NJ).
Briefly, 5ng of the pET11a plasmid harboring the srtA gene was transformed into
competent E. coli BL21 (DE3) (New England BioLabs, Ipswich, MA) by heat shock
for exactly 10s at 42°C. The mixture was immediately placed on ice for 5min and
950μl of SOC outgrowth medium (New England BioLabs, Ipswich, MA) was added,
and allowed to incubate at 37°C with shaking for 1hr. After 1hr, 25μl and 75μl of
the transformed E.coli was plated on pre-warmed LB-amp (Luria-Bertani with
100μg/ml ampicillin) plates and incubated overnight at 37°C.
Recombinant colonies were picked and inoculated into LB-amp broth and grown
overnight at 37°C on a shaker incubator at 225rpm. One milliliter of overnight
culture was inoculated into 100ml of LB-amp broth and allowed to grow till an
OD600=0.4-0.6 was reached. Protein expression was induced by adding 1mM
isopropyl 1-thio-β-d-galactopyranoside (IPTG, Sigma-Aldrich, St.Louis, MO) at
30°C for ~4hr. Cells were harvested by centrifugation at 10,000xg for 30min. The
bacterial pellet was resuspended in 5ml of Bug Buster solution (Millipore-Novagen,
Temecula, CA) along with protease inhibitor cocktail IV (Millipore-Calbiochem, San
Diego, CA) and incubated at room temperature for 20-30min with shaking to
facilitate cell lysis. The lysate was clarified by centrifugation at 10,000g for 30min
at 4°C and recombinant protein was enriched on an Ni-TED column (PrepEase
His-tagged protein purification kit, Affymetrix Inc, Santa Clara, CA) and His-tagged
SrtA was eluted from the column as per the manufacturer’s protocol. The purity of
the protein was determined by SDS-PAGE and western blot using monoclonal antiHis antibody-HRP conjugate (Thermo Scientific, Rockford, IL).
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Homology Modeling of Sortase A and Virtual Screening for Sortase A
Inhibitors

The predicted S. pseudintermedius SrtA protein sequence was compared to that
of S. aureus SrtA using the BLAST algorithm and conserved domain search
feature in NCBI. The proteins share 57% identity at the amino acid level. His114,
Cys177 and Arg190 are predicted to be a part of the catalytic triad site involved in
attacking the LPXTG motif in S. pseudintermedius [68]. Molecular Dynamic (MD)
simulation was performed using the bioinformatics tool MOE (Molecular Operating
Environment)

to

generate

a

3-D

homology

model

of

S. pseudintermedius SrtA. Enzyme coordinates were mapped and the catalytic
and active sites including the amino acids involved in substrate binding were
predicted. The enzyme structure at one of many coordinates was fixed and this
structure was initially used to screen the drug database NCI (National Cancer
Institute). Compounds predicted to bind to the active site were identified. Initially,
from the 200 highest ranked compounds, twenty were selected. Of the 20, the 10
most active compounds were purchased and tested in the in vitro assay.
For the second iteration, compounds that showed >50% inhibition in the in vitro
assay were selected. The common structural features of these compounds were
identified in an attempt to find inhibitors with higher binding affinities for SrtA. With
the refined search parameters, the drug database Zinc was screened. Ten
compounds were evaluated for their inhibitory potential in the in vitro assay.

Enzymatic Activity of Sortase A

The functional activity of recombinant SrtA was performed in 96-well black
microtiter plates with clear bottom (Corning, Fisher Scientific, Hampton, NH) in a
final reaction volume of 200μl. Fluorescent- quenched bacterial sortase substrate
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III, Abz/DNP (Abz-LPETG-K(Dnp)-NH2 (GenScript Inc., Piscataway, NJ) dissolved
in isopropanol was used for Km determination. Varying concentrations of the
substrate (2.5μM - 200μM) were incubated at 25°C with 1μM of SrtA diluted in
assay buffer (50mM Tris-HCl, 150mM NaCl, 5mM CaCl2, and 0.1% Triton X-100,
pH 7.5). The increase in fluorescence was measured in a kinetic assay for 20min
at 2min intervals using a Synergy HTX multimode reader (BioTek, Winooski, VT)
at wavelengths 320 excitation/420 emission. The initial velocity V0 was determined
from the linear portion of the curve and the Km was determined using the MichaelisMenten equation where V=Vmax[S]/([S]+Km).

In vitro Sortase Inhibition

The assay developed by Kruger et al. was modified and used to determine the
activity of recombinant SrtA [176]. Bacterial sortase substrate III, Abz/DNP (AbzLPETG-K(Dnp)-NH2 (GenScript Inc., Piscataway, NJ) was dissolved in
isopropanol to a final concentration of 1mM. Recombinant SrtA was pre-incubated
with varying amounts of the inhibitor at 37°C for 30min. One hundred micromolar
of the FRET substrate was added to the wells of a 96-well black microtiter plate
with clear bottom (Corning, Fisher Scientific, Hampton, NH). One hundred
microliters of the SrtA-inhibitor mixture was added and the incubated at room
temperature for 20min. The amount of fluorescence was measured using a
Synergy HTX multimode reader (BioTek, Winooski, VT) at wavelengths 320
excitation/420 emission. A titration experiment was performed to determine the
optimal amount of the enzyme and inhibitor to be used for each assay.
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Sortase Inhibition in Bacterial Cells
Bacterial colonies from blood agar plates were inoculated into 5ml of TSB and
grown overnight at 37°C with shaking. Fifty microliters of overnight culture were
inoculated into 5ml of fresh TSB along with 100μg/ml of the inhibitor and allowed
to grow until log phase (OD600 = 0.4-0.6) was reached. One milliliter of culture was
aliquoted into a micro centrifuge tube and centrifuged at 10,000xg for 1min. The
pellet was washed twice and suspended in 1ml of PBS. One hundred microliters
of chicken anti-protein A antibody conjugated to FITC (Gallus Immunotech, Cary,
NC) was added and incubated at room temperature for 30min in the dark. Unbound
antibody was washed off and the pellet was suspended in a final volume of 1ml
PBS. The amount of bound fluorescent antibody was measured by flow cytometry
using an attune acoustic focusing cytometer (Applied Biosystems, Foster City, CA)
at excitation/emission wavelengths of 488/519 nm. Data were acquired in linear
mode for forward and side scatter and logarithmic mode for fluorescence. For each
sample, 10,000 events were measured. Also, for each isolate, cells incubated with
PBS instead of the inhibitor served as the negative control to distinguish between
inhibition and non-inhibition.

Statistical Analysis
A one-way ANOVA and multiple comparisons using Tukey’s honest significant
difference were performed to test if there was a significant difference in the
expression of srtA among bacterial isolates, and also to determine if there was a
significant difference in the inhibition assay. Each experiment was repeated at
least three times and a p-value of <0.05 was considered significant. All analyses
were conducted using the GraphPad Prism software (Version 7, GraphPad
Software Inc, La Jolla, CA).
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Results
S. pseudintermedius contains an srtA Gene Homologous to srtA Found in S.
aureus

Whole genome sequence analysis of several S. pseudintermedius isolates
revealed that S. pseudintermedius contained a srtA gene homologous to the one
found in S.aureus. The srtA gene in S.pseudintermedius is 597bp in length and
codes for a 198 amino acid protein (Figure 5.1) with a predicted molecular weight
of 22.36kDa.
Conventional PCR with S. pseudintermedius srtA-specific primers showed that
isolates representing the major clonal populations in the United States and Europe
(Table 5.1) contained the srtA gene. qPCR data suggested that the fold change in
expression for isolates 08-1294 and 08-521a were 0.76 fold and 0.4 fold
respectively. Fold change in expression for isolates form sequence type ST71
were 0.75 fold (08-1661), 4.12 fold (E140) and 3.47 fold (NA16). Isolate 06- 3228
was assigned as the calibrator for this experiment. The amount of srtA mRNA was
normalized against 16S rRNA as the endogenous control (Figure 5.2). These
results indicate that the srtA mRNA in S. pseudintermedius could be detected and
quantified.

Recombinant S. pseudintermedius SrtA

The full-length recombinant, his-tagged SrtA protein was purified from E. coli BL21
(DE3). The molecular weight of the recombinant protein was ~23kDa and was
confirmed by SDS-PAGE and western blot (Figure 5.3). The concentration of the
protein was estimated by Bradford method and found to be 0.5-1mg/ml per 100ml
batch of E. coli culture.
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ATGCAAAAATTAACACGTGGGTTGGTTCCACTTATTGGTATTGCATTGATTTTAGCAGG
CGTATATTTAATCTTTAAGCCGAAAATTGATGCATATTTGACCAATAAAGAAAATGAAC
AAAAAATTGAAGTATATGAAGAAAGTCAACAAAATGCACCATCAAAAGTGCCTGAAATT
CCGAAAGACCCGTCGAAAGTCGTTGGTGTATTAGAAGTGCCGTCAGTCGGTATAAAAGA
AGCTGTGTATCCTGGTCCTGCGACACCTGAACAATTGGAGCGCGGTGTCAGTTTGGCGG
AAAAGGATGAATCACTCAAAGACCAAAATATCGCTATTGCGGGACATACGAATTATAGT
TTGAACTATCAATTTACAGAGTTACACAAAGCGAAAAAGGGTGCAGAAGTAATTTTTAA
ACTGGGTAAAGAAACGCGCAAATATCAAATTACGTCGATTAAAGATGTCGATCCGTATC
AAGTTGAAGTGTTGGAAGAGATGAAGAAAGATAAAGACCAACTGACACTCATTACTTGT
GATGATTACGATGAGAAAACAGGTCAGTGGCTGACACGCAAAATTTATGTAGCTGAACG
TGTGTAG
MQKLTRGLVPLIGIALILAGVYLIFKPKIDAYLTNKENEQKIEVYEESQQNAPSKVPEI
PKDPSKVVGVLEVPSVGIKEAVYPGPATPEQLERGVSLAEKDESLKDQNIAIAGHTNYS
LNYQFTELHKAKKGAEVIFKLGKETRKYQITSIKDVDPYQVEVLEEMKKDKDQLTLITC
DDYDEKTGQWLTRKIYVAERV

Figure 5.1 Consensus gene sequence and predicted amino acid sequence of
SrtA in S. pseudintermedius.
The srtA gene in S. pseudintermedius is 597bp in length and codes for a protein
with 198 amino acids. Based on amino acid conservation with S. aureus SrtA, the
amino acids predicted to be critical for enzymatic activity are highlighted.
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Figure 5.2 Expression levels of srtA in S. pseudintermedius.
Quantitative real-time PCR was used to measure the amount of srtA mRNA in log
phase bacterial cells. Relative gene expression was calculated using the ΔΔCT
method and expressed as fold change. 16S rRNA was used as the endogenous
control. The values represent the average from three independent experiments.
(*P<0.05 was considered significant).

116

Figure 5.3 SDS-PAGE and Western Blot analysis of recombinant SrtA.
Western blot analysis of recombinant SrtA in one of the elution fractions using antiHis antibody. The molecular weight of the protein corresponded to ~23kDa. E1, E2
and E3 are three separate elution fractions.
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3-D homology model of SrtA and Identifying Sortase Inhibitors
The S. pseudintermedius SrtA protein sequence was compared to that of S.aureus
SrtA. Molecular Dynamic (MD) simulation was performed using the bioinformatics
tool MOE (Molecular Operating Environment) to generate a 3-D homology model
of S. pseudintermedius SrtA. A potential structure of SrtA was built and atomic
coordinates for the protein, including for the active site’s amino acids involved in
substrate binding, were generated. The predicted 3-D homology model of SrtA with
a potential inhibitor bound to its active site is shown in Figure 5.4.
Inhibition of SrtA activity in vitro

To determine the activity of recombinant SrtA, an in vitro functional assay using
the synthetic SrtA substrate, bacterial sortase substrate III, Abz/DNP (Abz-LPETGK(Dnp)-NH2 was performed. Functional SrtA cleaves the substrate between
threonine (T) and glycine (G) and this is measured by an increase in fluorescence.
A dose dependent increase in the cleavage of the substrate was observed when
1μM of recombinant SrtA was used in the FRET assay (Figure 5.5).
Next, to determine the inhibitory potential of the compounds from NCI, recombinant
SrtA was pre-incubated with the inhibitors at 37°C for 30min and the FRET assay
was performed. From the first round of screening, four out of the ten compounds
from NCI (117466, 117922, 64876 and 1847) showed between 40-60% inhibition
of SrtA. Of these, Compound 1847 consistently showed 50-80% inhibition of
recombinant SrtA depicted in (Figure 5.6). MTSET which is a known inhibitor of
SrtA [70] was used as the control and showed 57.5% inhibition in this assay.
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Figure 5.4 3-D homology model of SrtA.
3-D homology model of S. pseudintermedius SrtA with a representative inhibitor
(shown in green) bound to the active site. The β-sheets, α-helices and loop regions
are indicated in yellow, red and blue respectively.
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Figure 5.5 SrtA functional assay.
The activity of recombinant of SrtA was measured using a FRET assay. Varying
concentrations of the FRET substrate were incubated with 1μM of the enzyme.
The cleavage of the substrate was monitored by measuring an increase in
fluorescence.
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Figure 5.6 First round of screening for inhibitors.
Compounds from NCI tested for their ability to inhibit SrtA in the in vitro FRETbased functional assay. Four of the ten compounds showed ~40%-60% inhibition
of Srt A. The values represent average from three independent experiments.
(*P<0.05 was considered significant).

121

Since compound 1847 showed promising results, the second search iteration was
based on the structure of 1847 to identify similar compounds but with higher
inhibitory potential. Four compounds were identified from the Zinc database. Of
the four compounds, only one compound, 5930504, showed 51.76% inhibition.
5510335 and STL223442 showed 9.88% and 13.75% inhibition respectively.
SKT022091 did not have inhibitory effect on SrtA. However, none of the
compounds from Zinc were better than the parent compound, 1847 (Figure 5.7).

Inhibition of SrtA Activity during Bacterial Growth

SrtA catalyzes the anchoring of surface proteins with a specific LPXTG motif on to
the peptidoglycan cell wall during active bacterial growth (log phase). Inhibition of
SrtA in bacterial cells should result in decreased amounts of cell wall-associated
proteins harboring the LPXTG motif.

This can be measured indirectly by

measuring the decrease in the density of cell-wall associated LPXTG proteins. In
S. pseudintermedius, there are several proteins with a predicted LPXTG motif,
including but not limited to protein A, clumping factors A and B, fibrinogen binding
protein and fibronectin binding protein. In this assay, the inhibition of SrtA was
measured indirectly by measuring the decrease in the amount of Protein A on the
bacterial surface using flow cytometry. Five representative S. pseudintermedius
isolates were tested. Isolates 06-3228, 08-1661, NA12 and NA16 showed 38.7%,
74.3%, 42.8% and 89.4% reduction in the density cell wall-associated Protein A
compared to the respective controls without the inhibitor for each isolate, as a
result of SrtA inhibition (Figure 5.8). Isolate NA45 was not affected by compound
1847. These results suggest that compared to the controls (without inhibitor), the
bacterial cells exposed to the inhibitor 1847 showed a decrease in the density of
cell wall-associated Protein A due to inhibition of SrtA.
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Figure 5.7 Second round of screening for inhibitors.
Inhibitory effect of compounds from ZINC. Of the four compounds tested, only
5930504 showed ~50% inhibition of Srt A in the in-vitro FRET-based functional
assay. 5510335 and STL223422 showed 10-20% inhibition while STK022091 did
not have any inhibitory effect on SrtA. The values represent average from three
independent experiments. (*P<0.05 was considered significant).
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Figure 5.8 Inhibition of SrtA in whole bacterial cells.
Four bacterial isolates 08-3228, 08-1661, NA12 and NA16 were grown in presence
of inhibitor 1847 till exponential log phase. SrtA inhibition was measured indirectly
by measuring the decrease in the density of cell wall associated Protein A (one of
the LPXTG proteins targeted by SrtA) using flow cytometry. The values represent
average from three independent experiments. (*P<0.05 was considered
significant). Isolate NA45 which does not express functional Protein A on its
surface was not affected by inhibitor 1847.
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To determine the effect of inhibitor on bacterial viability, bacterial growth was
monitored in the presence and absence of inhibitors at varying concentrations.
Bacterial growth was determined by measuring the turbidity of the culture medium
at A600. It was found that the bacterial growth remained unaffected in the presence
of the inhibitor suggesting that the inhibitor affected the function of SrtA but had no
direct effect on growth of the bacteria.

Discussion
In the last decade, there has been a steady increase in the incidence of
microorganisms with resistance to methicillin both in human and veterinary
medicine [80, 92]. Most of the organisms that display methicillin resistance are also
multidrug resistant and cannot be treated with conventional antibiotics. This is
particularly difficult in the veterinary setting due to the limited number of antibiotic
choices that are approved for treatment [81]. Hence, there is an urgent need for
the development of novel therapeutics that can be administered either
prophylactically or after the onset of infection. Ideally, any novel therapeutic should
not have a high level of selective pressure that is observed with current antibiotics.
This will help reduce the risk of developing new forms of resistance [177].
Cell wall-associated (CWA) proteins are responsible for virulence and immune
evasion in staphylococci [126]. SrtA is a cysteine transpeptidase produced by most
Gram positive bacteria. It catalyzes the anchoring of proteins harboring the LPXTG
motif on to the peptidoglycan cell wall [58, 62]. Inhibition of SrtA will prevent
proteins harboring the LPXTG motif from anchoring on to the cell wall, thereby
preventing the interaction between the CWA proteins and the host. Since this is a
crucial step in the establishment of infection, inhibiting SrtA would make the
bacteria less virulent [56, 57, 70, 124]. Inhibition of SrtA has several advantages.
(a) Firstly, SrtA is expressed on the outside of the bacterial cell membrane which
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makes it readily accessible to inhibitors without the need for penetrating the cell
membrane, (b) SrtA inhibition will not affect the viability of the bacteria directly.
Therefore, the risk of bacteria developing resistance against the inhibitor is greatly
reduced and (c) there is no known homologue for SrtA in eukaryotes, thus it is
possible to achieve selectivity more easily. SrtA inhibition has been extensively
studied in S. aureus [71, 175]. Virtual screening of drug databases to identify
inhibitors for S. aureus SrtA has also been explored [70, 74].
In this study, recombinant SrtA from S. pseudintermedius was expressed and
purified from E. coli. A homology model of the enzyme was generated. Using this
model, virtual screening of NCI database for compounds that bind to the catalytic
site of SrtA was performed. Ten compounds were selected and tested for their
abilities to inhibit recombinant SrtA in an in vitro FRET-based assay. Compound
1847 consistently showed >50% inhibition in this assay. The structure of 1847 was
used as the template to screen a second database, Zinc, in an attempt to find
compounds with higher inhibitory potential. Four compounds were identified and
tested again using the in vitro FRET-based assay, although none of the new
compounds were better than the parent compound, 1847. Since 1847 was the
most promising candidate, it was tested in whole bacterial cells during active
growth phase to determine its ability to inhibit SrtA. The results showed that in all
of the bacterial isolates tested, except NA45, there was between 35%-80%
reduction in the amount of CWA Protein A, suggesting that SrtA inhibition could
work as an anti-infective therapy against staphylococcal infections. Future
experiments in this study include analysis of enzyme kinetic parameters, target
validation using surface plasmon resonance and/or isothermal colorimetry, side
chain modification to enhance the inhibitory potential of compound 1847 and
finally, testing the inhibitor in an animal model of S. pseudintermedius infection.
The role of SrtA in anchoring CWA proteins and its contribution to virulence is not
just limited to staphylococcal species. SrtA and surface proteins with LPXTG
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sorting signals have also been studied in streptococcal species and other
nosocomial pathogens like Enterococcus faecalis, Enterococcus faecium, and
Clostridium difficile [58]. Therefore, small molecule inhibitors that can specifically
block sortase-catalyzed transpeptidation reaction could work against a broad
spectrum of pathogenic, antibiotic-resistant Gram-positive bacteria.
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CONCLUSION
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Conclusions and Recommendations
The canine pathogen S. pseudintermedius has been associated with an increased
prevalence of methicillin resistance and multidrug resistance. Due to the limited
number of antibiotics available for treatment in the veterinary setting, it is important
to develop novel strategies to treat or prevent infection. Understanding the nature
of immune response to S. pseudintermedius infection is crucial for vaccine
development.
Characterization of the virulence factor Protein A in S. pseudintermedius has
provided information about the nature of canine IgG binding to this protein. It is
now evident that the most predominant clonal populations in the United States and
Europe, ST68 and ST71 respectively, bind higher amounts of canine IgG and antiProtein A antibody, suggesting that these sequence types may express a higher
amount of Protein A on their surface. Protein A binds to canine IgG via its Fc
region. This binding in the ‘wrong’ orientation facilitates Protein A to function as an
immune evasion factor by preventing opsonization and phagocytosis. This has
also been demonstrated in canine blood, neutrophils and DH82 macrophage-like
cell line wherein pre-incubation of bacteria with anti-Protein A antibody enhances
phagocytosis. Once the IgG-binding sites on Protein A are identified, it will be
possible to generate a non-toxigenic form of the protein that can be tested both in
vitro and in vivo as a potential vaccine candidate.
S. pseudintermedius employs several immune evasion strategies to persist in the
host and establish infection. Inhibiting one virulence/immune evasion factor may
not be the best strategy for treatment of infection. Instead, targeting a global
protein or enzyme that is central to the regulation of multiple virulence factors could
be a potential strategy to combat infection. Sortase A is a transpeptidase enzyme
produced by all Gram-positive bacteria that is responsible for anchoring proteins
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with an LPXTG domain onto the peptidoglycan cell well. Most proteins with an
LPXTG domain are potent virulence factors. In this study, the possibility of
inhibiting Sortase A as an anti-infective therapy was explored. 3-D homology
modeling and molecular dynamic simulation helped map the active site of Sortase
A. Virtual screening of drug databases provided a list of potential inhibitors that
were tested both in an in vitro assay and in bacterial cells. Compounds that were
able to inhibit the activity of Sortase A were identified. Further optimization and
testing of the compounds in an animal model could prove to be useful in
determining if co-administration of a Sortase A inhibitor along with antibiotic
treatment will be a more effective treatment strategy than what is currently being
followed.
Several studies with S. aureus have indicated that a successful vaccine could be
one with several different antigenic determinants (multivalent vaccine) that can
stimulate both B-cell and T-cell responses. Keeping these factors in mind, the
secretome, surface-associated proteins and IgG-binding proteins from three
representative sequence types were analyzed by mass spectrometry. From the
data, eight target proteins were identified across all three sequence types. Further
testing and characterization of these proteins need to be performed.
This work has laid the foundation for identifying, characterizing and testing proteins
that could serve as potential vaccine candidates, and explore non-antibiotic
strategies such as Sortase A inhibition as alternate anti-infective therapy against
methicillin-resistant S. pseudintermedius infection.
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